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Overwhelming evidence shows the quality of reporting of randomised controlled trials (RCTs) is not
optimal. Without transparent reporting, readers cannot judge the reliability and validity of trial ﬁndings
nor extract information for systematic reviews. Recent methodological analyses indicate that inadequate
reporting and design are associated with biased estimates of treatment effects. Such systematic error is
seriously damaging to RCTs, which are considered the gold standard for evaluating interventions because
of their ability to minimise or avoid bias.
A group of scientists and editors developed the CONSORT (Consolidated Standards of Reporting Trials)
statement to improve the quality of reporting of RCTs. It was ﬁrst published in 1996 and updated in 2001.
The statement consists of a checklist and ﬂow diagram that authors can use for reporting an RCT. Many
leading medical journals and major international editorial groups have endorsed the CONSORT state-
ment. The statement facilitates critical appraisal and interpretation of RCTs.
During the 2001 CONSORT revision, it became clear that explanation and elaboration of the principles
underlying the CONSORT statement would help investigators and others to write or appraise trial reports.
A CONSORT explanation and elaboration article was published in 2001 alongside the 2001 version of the
CONSORT statement.
After an expert meeting in January 2007, the CONSORT statement has been further revised and is
published as the CONSORT 2010 Statement. This update improves the wording and clarity of the previous
checklist and incorporates recommendations related to topics that have only recently received recog-
nition, such as selective outcome reporting bias.
This explanatory and elaboration documentdintended to enhance the use, understanding, and
dissemination of the CONSORT statementdhas also been extensively revised. It presents the meaning
and rationale for each new and updated checklist item providing examples of good reporting and, where
possible, references to relevant empirical studies. Several examples of ﬂow diagrams are included.
The CONSORT 2010 Statement, this revised explanatory and elaboration document, and the associated
website (www.consort-statement.org) shouldbehelpful resources to improve reportingof randomised trials.
 2010 Moher et al, reprinted by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (http://creative-
commons.org/licenses/by/2.0) which permits unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are credited.he terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and repro-
rk is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://
reativecommons.org/licenses/by-nc/2.0/legalcode.
ORT 2010 Statement, this article is freely accessible on bmj.com and has also been published in the Journal of Clinical
of this article. For details on further use, see the CONSORT website (www.consort-statement.org).
by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open-access article distributed under the terms of the Creative Commons
.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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GUIDELINE“Thewhole of medicine depends on the transparent reporting of
clinical trials”.1 Box 1. Treatment allocation. What’s so special aboutrandomisation?
The method used to assign interventions to trial partici-
pants is a crucial aspect of clinical trial design. Random
assignment is the preferred method; it has been success-
fully used regularly in trials for more than 50 years.24 Ran-
domisation has three major advantages.25 First, when
properly implemented, it eliminates selection bias,
balancing both known and unknown prognostic factors, in
the assignment of treatments. Without randomisation,
treatment comparisons may be prejudiced, whether
consciously or not, by selection of participants of a partic-
ular kind to receive a particular treatment. Second, random
assignment permits the use of probability theory to expressWell designed and properly executed randomised controlled
trials (RCTs) provide the most reliable evidence on the efﬁcacy of
healthcare interventions, but trials with inadequate methods are
associated with bias, especially exaggerated treatment effects.2e5
Biased results from poorly designed and reported trials can
mislead decision making in healthcare at all levels, from treatment
decisions for a patient to formulation of national public health
policies.
Critical appraisal of the quality of clinical trials is possible only if
the design, conduct, and analysis of RCTs are thoroughly and
accurately described in the report. Far from being transparent, the
reporting of RCTs is often incomplete,6e9 compounding problems
arising from poor methodology.10e15the likelihood that any difference in outcome between
intervention groups merely reflects chance.26 Third,
random allocation, in some situations, facilitates blinding
the identity of treatments to the investigators, participants,
and evaluators, possibly by use of a placebo, which reduces
bias after assignment of treatments.27 Of these three
advantages, reducing selection bias at trial entry is usually
the most important.28
Successful randomisation in practice depends on two
interrelated aspectsdadequate generation of an unpre-
dictable allocation sequence and concealment of that
sequence until assignment occurs.2,23 A key issue is
whether the schedule is known or predictable by the people
involved in allocating participants to the comparison
groups.29 The treatment allocation system should thus be
set up so that the person enrolling participants does not
know in advance which treatment the next person will get,
a process termed allocation concealment.2,23 Proper allo-
cation concealment shields knowledge of forthcoming
assignments, whereas proper random sequences prevent
correct anticipation of future assignments based on
knowledge of past assignments.
Unfortunately, despite that central role, reporting of the
methods used for allocation of participants to interventions
is also generally inadequate. For example, 5% of 206 reports1. Incomplete and inaccurate reporting
Many reviews have documented deﬁciencies in reports of clin-
ical trials. For example, information on the method used in a trial to
assign participants to comparison groups was reported in only 21%
of 519 trial reports indexed in PubMed in 2000,16 and only 34% of
616 reports indexed in 2006.17 Similarly, only 45% of trial reports
indexed in PubMed in 200016 and 53% in 200617 deﬁned a primary
endpoint, and only 27% in 2000 and 45% in 2006 reported a sample
size calculation. Reporting is not only often incomplete but also
sometimes inaccurate. Of 119 reports stating that all participants
were included in the analysis in the groups to which they were
originally assigned (intention-to-treat analysis), 15 (13%) excluded
patients or did not analyse all patients as allocated.18 Many other
reviews have found that inadequate reporting is common in
specialty journals16,19 and journals published in languages other
than English.20,21
Proper randomisation reduces selection bias at trial entry and is
the crucial component of high quality RCTs.22 Successful random-
isation hinges on two steps: generation of an unpredictable allo-
cation sequence and concealment of this sequence from the
investigators enrolling participants (see Box 1).2,23of supposed RCTs in obstetrics and gynaecology journals
described studies that were not truly randomised.23 This
estimate is conservative, as most reports do not at present
provide adequate information about the method of alloca-
tion.20,23,30e332. Improving the reporting of RCTs: the CONSORT statement
DerSimonian and colleagues suggested that “editors could
greatly improve the reporting of clinical trials by providing authors
with a list of items that they expected to be strictly reported.”34
Early in the 1990s, two groups of journal editors, trialists, and
methodologists independently published recommendations on the
reporting of trials.35,36 In a subsequent editorial, Rennie urged the
two groups to meet and develop a common set of recommenda-
tions37; the outcome was the CONSORT statement (Consolidated
Standards of Reporting Trials).38
The CONSORT statement (or simply CONSORT) comprises
a checklist of essential items that should be included in reports
of RCTs and a diagram for documenting the ﬂow of participants
through a trial. It is aimed at primary reports of RCTs with two
groups, parallel designs. Most of CONSORT is also relevant to
a wider class of trial designs, such as non-inferiority, equiva-
lence, factorial, cluster, and crossover trials. Extensions to the
CONSORT checklist for reporting trials with some of these
designs have been published,39e41 as have those for reporting
certain types of data (harms42), types of interventions (non-
pharmacological treatments,43 herbal interventions44), and
abstracts.45
The objective of CONSORT is to provide guidance to authors
about how to improve the reporting of their trials. Trial reportsneed be clear, complete, and transparent. Readers, peer reviewers,
and editors can also use CONSORT to help them critically appraise
and interpret reports of RCTs. However, CONSORT was not meant to
be used as a quality assessment instrument. Rather, the content of
CONSORT focuses on items related to the internal and external
validity of trials. Many items not explicitly mentioned in CONSORT
should also be included in a report, such as information about
approval by an ethics committee, obtaining informed consent from
participants, and, where relevant, existence of a data safety and
monitoring committee. In addition, any other aspects of a trial that
are mentioned should be properly reported, such as information
pertinent to cost effectiveness analysis.46e48
Since its publication in 1996, CONSORT has been supported by
more than 400 journals (www.consort-statement.org) and several
editorial groups, such as the International Committee of Medical
Journal Editors.49 The introduction of CONSORT within journals is
associated with improved quality of reports of RCTs.17,50,51 However,
CONSORT is an ongoing initiative, and the CONSORT statement is
revised periodically.3 CONSORT was last revised nine years ago, in
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GUIDELINE2001.52e54 Since then theevidencebase to informCONSORThasgrown
considerably; empirical datahavehighlightednewconcerns regarding
the reporting of RCTs, such as selective outcome reporting.55e57 A
CONSORT Group meeting was therefore convened in January 2007, in
Canada, to revise the 2001 CONSORT statement and its accompanying
explanation and elaboration document. The revised checklist is shown
in Table 1 and the ﬂow diagram, not revised, in Fig. 1.52e54
3. The CONSORT 2010 statement: explanation and elaboration
During the 2001 CONSORT revision, it became clear that
explanation and elaboration of the principles underlying the
CONSORT statement would help investigators and others to write
or appraise trial reports. The CONSORT explanation and elaboration
article58 was published in 2001 alongside the 2001 version of the
CONSORT statement. It discussed the rationale and scientiﬁc
background for each item and provided published examples of
good reporting. The rationale for revising that article is similar to
that for revising the statement, described above. We brieﬂy
describe below the main additions and deletions to this version of
the explanation and elaboration article.
4. The CONSORT 2010 explanation and elaboration: changes
We have made several substantive and some cosmetic changes
to this version of the CONSORT explanatory document (full details
are highlighted in the 2010 version of the CONSORT statement59).
Some reﬂect changes to the CONSORT checklist; there are three
new checklist items in the CONSORT 2010 checklistdsuch as item
24, which asks authors to report where their trial protocol can be
accessed. We have also updated some existing explanations,
including adding more recent references to methodological
evidence, and used some better examples. We have removed the
glossary, which is now available on the CONSORT website (www.
consort-statement.org). Where possible, we describe the ﬁndings
of relevant empirical studies. Many excellent books on clinical trials
offer fuller discussion of methodological issues.60e62 Finally, for
convenience, we sometimes refer to “treatments” and “patients”,
although we recognise that not all interventions evaluated in RCTs
are treatments and not all participants are patients.
5. Checklist items
5.1. Title and abstract
5.1.1. Item 1a. Identiﬁcation as a randomised trial in the title
Exampled“Smoking reduction with oral nicotine inhalers:
double blind, randomised clinical trial of efﬁcacy and safety.”63
ExplanationdThe ability to identify a report of a randomised
trial in an electronic database depends to a large extent on how it
was indexed. Indexers may not classify a report as a randomised
trial if the authors do not explicitly report this information.64 To
help ensure that a study is appropriately indexed and easily iden-
tiﬁed, authors should use the word “randomised” in the title to
indicate that the participants were randomly assigned to their
comparison groups.
5.1.2. Item 1b. Structured summary of trial design, methods, results,
and conclusions
For speciﬁc guidance see CONSORT for abstracts.45,65
ExplanationdClear, transparent, and sufﬁciently detailed
abstracts are important because readers often base their assessment
of a trial on such information. Some readers use an abstract as
a screening tool to decide whether to read the full article. However,
as not all trials are freely available and some health professionals donot have access to the full trial reports, healthcare decisions are
sometimes made on the basis of abstracts of randomised trials.66
A journal abstract should contain sufﬁcient information about
a trial to serve as an accurate record of its conduct and ﬁndings,
providing optimal information about the trial within the space
constraints and format of a journal. A properly constructed and
written abstract helps individuals to assess quickly the relevance of
the ﬁndings and aids the retrieval of relevant reports from elec-
tronic databases.67 The abstract should accurately reﬂect what is
included in the full journal article and should not include infor-
mation that does not appear in the body of the paper. Studies
comparing the accuracy of information reported in a journal
abstract with that reported in the text of the full publication have
found claims that are inconsistent with, or missing from, the body
of the full article.68e71 Conversely, omitting important harms from
the abstract could seriously mislead someone’s interpretation of
the trial ﬁndings.42,72
A recent extension to the CONSORT statement provides a list of
essential items that authors should include when reporting the
main results of a randomised trial in a journal (or conference)
abstract (see Table 2).45 We strongly recommend the use of struc-
tured abstracts for reporting randomised trials. They provide
readers with information about the trial under a series of headings
pertaining to the design, conduct, analysis, and interpretation.73
Some studies have found that structured abstracts are of higher
quality than the more traditional descriptive abstracts74,75 and that
they allow readers to ﬁnd information more easily.76 We recognise
that many journals have developed their own structure and word
limit for reporting abstracts. It is not our intention to suggest
changes to these formats, but to recommend what information
should be reported.
5.2. Introduction
5.2.1. Item 2a. Scientiﬁc background and explanation of rationale
Exampled“Surgery is the treatment of choice for patients with
disease stage I and II non-small cell lung cancer (NSCLC) . An
NSCLC meta-analysis combined the results from eight randomised
trials of surgery versus surgery plus adjuvant cisplatin-based
chemotherapy and showed a small, but not signiﬁcant (p ¼ 0.08),
absolute survival beneﬁt of around 5% at 5 years (from 50% to 55%).
At the time the current trial was designed (mid-1990s), adjuvant
chemotherapy had not become standard clinical practice . The
clinical rationale for neo-adjuvant chemotherapy is three-fold:
regression of the primary cancer could be achieved thereby facili-
tating and simplifying or reducing subsequent surgery; undetected
micro-metastases could be dealt with at the start of treatment; and
theremight be inhibition of the putative stimulus to residual cancer
by growth factors released by surgery and by subsequent wound
healing . The current trial was therefore set up to compare, in
patients with resectable NSCLC, surgery alone versus three cycles of
platinum-based chemotherapy followed by surgery in terms of
overall survival, quality of life, pathological staging, respectability
rates, extent of surgery, and time to and site of relapse”.77
ExplanationdTypically, the introduction consists of free ﬂow-
ing text, in which authors explain the scientiﬁc background and
rationale for their trial, and its general outline. It may also be
appropriate to include here the objectives of the trial (see item 2b).
The rationale may be explanatory (for example, to assess the
possible inﬂuence of a drug on renal function) or pragmatic (for
example, to guide practice by comparing the beneﬁts and harms of
two treatments). Authors should report any evidence of the bene-
ﬁts and harms of active interventions included in a trial and should
suggest a plausible explanation for how the interventions might
work, if this is not obvious.78
Table 1
CONSORT 2010 checklist of information to include when reporting a randomised trial.a
Section/Topic Item No Checklist item Reported on page No
Title and abstract
1a Identiﬁcation as a randomised trial in the title
1b Structured summary of trial design, methods, results,
and conclusions (for speciﬁc guidance see CONSORT for abstracts45 65)
Introduction
Background and objectives 2a Scientiﬁc background and explanation of rationale
2b Speciﬁc objectives or hypotheses
Methods
Trial design 3a Description of trial design (such as parallel, factorial)
including allocation ratio
3b Important changes to methods after trial commencement
(such as eligibility criteria), with reasons
Participants 4a Eligibility criteria for participants
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufﬁcient details
to allow replication, including how and when they were actually administered
Outcomes 6a Completely deﬁned pre-speciﬁed primary and secondary
outcome measures, including how and when they were assessed
6b Any changes to trial outcomes after the trial commenced, with reasons
Sample size 7a How sample size was determined
7b When applicable, explanation of any interim
analyses and stopping guidelines
Randomisation:
Sequence generation 8a Method used to generate the random allocation sequence
8b Type of randomisation; details of any restriction
(such as blocking and block size)
Allocation
concealment mechanism
9 Mechanism used to implement the random allocation
sequence (such as sequentially numbered containers),
describing any steps taken to conceal the sequence
until interventions were assigned
Implementation 10 Who generated the random allocation sequence, who
enrolled participants, and who assigned participants to interventions
Blinding 11a If done, who was blinded after assignment to interventions
(for example, participants, care providers, those assessing outcomes) and how
11b If relevant, description of the similarity of interventions
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses
Results
Participant ﬂow
(a diagram is
strongly recommended)
13a For each group, the numbers of participants who were
randomly assigned, received intended treatment,
and were analysed for the primary outcome
13b For each group, losses and exclusions after randomisation,
together with reasons
Recruitment 14a Dates deﬁning the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group
Numbers analysed 16 For each group, number of participants (denominator) included in
each analysis and whether the analysis was by original assigned groups
Outcomes and estimation 17a For each primary and secondary outcome, results for each group, and the
estimated effect size and its precision (such as 95% conﬁdence interval)
17b For binary outcomes, presentation of both absolute and relative effect
sizes is recommended
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses
and adjusted analyses, distinguishing pre-speciﬁed from exploratory
Harms 19 All important harms or unintended effects in each group
(for speciﬁc guidance see CONSORT for harms42)
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias,
imprecision, and, if relevant, multiplicity of analyses
Generalisability 21 Generalisability (external validity, applicability) of the trial ﬁndings
Interpretation 22 Interpretation consistent with results, balancing beneﬁts
and harms, and considering other relevant evidence
Other information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders
a We strongly recommend reading this statement in conjunctionwith the CONSORT 2010 Explanation and Elaboration for important clariﬁcations on all the items. If relevant,
we also recommend reading CONSORT extensions for cluster randomised trials,40 non-inferiority and equivalence trials,39 non-pharmacological treatments,43 herbal inter-
ventions,44 and pragmatic trials.41 Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.
D. Moher et al. / International Journal of Surgery 10 (2012) 28e55 31
GUIDELINEThe Declaration of Helsinki states that biomedical research
involving people should be based on a thorough knowledge of the
scientiﬁc literature.79 That is, it is unethical to expose humans
unnecessarily to the risks of research. Some clinical trials have beenshown to have been unnecessary because the question they
addressed had been or could have been answered by a systematic
review of the existing literature.80,81 Thus, the need for a new trial
should be justiﬁed in the introduction. Ideally, it should include
Fig. 1. Flow diagram of the progress through the phases of a parallel randomised trial of two groups (that is, enrolment, intervention allocation, follow-up, and data analysis)52e54
D. Moher et al. / International Journal of Surgery 10 (2012) 28e5532
GUIDELINEa reference to a systematic reviewof previous similar trials or a note
of the absence of such trials.82
5.2.2. Item 2b. Speciﬁc objectives or hypotheses
Exampled“In the current study we tested the hypothesis that
a policy of active management of nulliparous labour would: 1.
reduce the rate of caesarean section, 2. reduce the rate of prolonged
labour; 3. not inﬂuence maternal satisfaction with the birth
experience”.83
ExplanationdObjectives are the questions that the trial was
designed to answer. They often relate to the efﬁcacy of a particular
therapeutic or preventive intervention. Hypotheses are pre-
speciﬁed questions being tested to help meet the objectives.
Hypotheses are more speciﬁc than objectives and are amenable toTable 2
Items to include when reporting a randomised trial in a journal abstract.
Item Description
Authors Contact details for the corresponding author
Trial design Description of the trial design (such as parallel,
cluster, non-inferiority)
Methods:
Participants Eligibility criteria for participants and the settings
where the data were collected
Interventions Interventions intended for each group
Objective Speciﬁc objective or hypothesis
Outcome Clearly deﬁned primary outcome for this report
Randomisation How participants were allocated to interventions
Blinding (masking) Whether participants, care givers, and those
assessing the outcomes were blinded
to group assignment
Results:
Numbers randomised Number of participants randomised to each group
Recruitment Trial status
Numbers analysed Number of participants analysed in each group
Outcome For the primary outcome, a result for each
group and the estimated effect size and its precision
Harms Important adverse events or side effects
Conclusions General interpretation of the results
Trial registration Registration number and name of trial register
Funding Source of fundingexplicit statistical evaluation. In practice, objectives and hypoth-
eses are not always easily differentiated. Most reports of RCTs
provide adequate information about trial objectives and
hypotheses.84
5.3. Methods
5.3.1. Item 3a. Description of trial design (such as parallel, factorial)
including allocation ratio
Exampled“This was a multicenter, stratiﬁed (6e11 years and
12e17 years of age, with imbalanced randomisation [2:1]), double
blind, placebo-controlled, parallel-group study conducted in the
United States (41 sites)”.85
ExplanationdThe word “design” is often used to refer to all
aspects of how a trial is set up, but it also has a narrower inter-
pretation. Many speciﬁc aspects of the broader trial design,
including details of randomisation and blinding, are addressed
elsewhere in the CONSORT checklist. Here we seek information on
the type of trial, such as parallel group or factorial, and the
conceptual framework, such as superiority or non-inferiority, and
other related issues not addressed elsewhere in the checklist.
The CONSORT statement focuses mainly on trials with partici-
pants individually randomised to one of two “parallel” groups. In
fact, little more than half of published trials have such a design.16
The main alternative designs are multi-arm parallel, crossover,
cluster,40 and factorial designs. Also, most trials are set to identify
the superiority of a new intervention, if it exists, but others are
designed to assess non-inferiority or equivalence.39 It is important
that researchers clearly describe these aspects of their trial,
including the unit of randomisation (such as patient, GP practice,
lesion). It is desirable also to include these details in the abstract
(see item 1b).
If a less common design is employed, authors are encouraged to
explain their choice, especially as such designs may imply the need
for a larger sample size ormore complex analysis and interpretation.
Although most trials use equal randomisation (such as 1:1 for
two groups), it is helpful to provide the allocation ratio explicitly.
For drug trials, specifying the phase of the trial (IeIV) may also be
relevant.
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GUIDELINE5.3.2. Item 3b. Important changes to methods after trial
commencement (such as eligibility criteria), with reasons
Exampled“Patients were randomly assigned to one of six
parallel groups, initially in 1:1:1:1:1:1 ratio, to receive either one of
ﬁve otamixaban . regimens . or an active control of unfractio-
nated heparin . an independent Data Monitoring Committee
reviewed unblinded data for patient safety; no interim analyses for
efﬁcacy or futility were done. During the trial, this committee
recommended that the group receiving the lowest dose of ota-
mixaban (0$035 mg/kg/h) be discontinued because of clinical
evidence of inadequate anticoagulation. The protocol was imme-
diately amended in accordance with that recommendation, and
participants were subsequently randomly assigned in 2:2:2:2:1
ratio to the remaining otamixaban and control groups,
respectively”.86
ExplanationdA few trials may start without any ﬁxed plan
(that is, are entirely exploratory), but the most will have a protocol
that speciﬁes in great detail how the trial will be conducted. There
may be deviations from the original protocol, as it is impossible to
predict every possible change in circumstances during the course of
a trial. Some trials will therefore have important changes to the
methods after trial commencement.
Changes could be due to external information becoming avail-
able from other studies, or internal ﬁnancial difﬁculties, or could be
due to a disappointing recruitment rate. Such protocol changes
should bemadewithout breaking the blinding on the accumulating
data on participants’ outcomes. In some trials, an independent data
monitoring committee will have as part of its remit the possibility
of recommending protocol changes based on seeing unblinded
data. Such changes might affect the study methods (such as
changes to treatment regimens, eligibility criteria, randomisation
ratio, or duration of follow-up) or trial conduct (such as dropping
a centre with poor data quality).87
Some trials are set up with a formal “adaptive” design. There is
no universally accepted deﬁnition of these designs, but a working
deﬁnition might be “a multistage study design that uses accumu-
lating data to decide how to modify aspects of the study without
undermining the validity and integrity of the trial.”88 The modiﬁ-
cations are usually to the sample sizes and the number of treatment
arms and can lead to decisions being made more quickly and with
more efﬁcient use of resources. There are, however, important
ethical, statistical, and practical issues in considering such
a design.89,90
Whether the modiﬁcations are explicitly part of the trial design
or in response to changing circumstances, it is essential that they
are fully reported to help the reader interpret the results. Changes
from protocols are not currently well reported. A review of
comparisons with protocols showed that about half of journal
articles describing RCTs had an unexplained discrepancy in the
primary outcomes.57 Frequent unexplained discrepancies have also
been observed for details of randomisation, blinding,91 and statis-
tical analyses.92
5.3.3. Item 4a. Eligibility criteria for participants
Exampled“Eligible participants were all adults aged 18 or over
with HIV who met the eligibility criteria for antiretroviral therapy
according to the Malawian national HIV treatment guidelines
(WHO clinical stage III or IV or any WHO stage with a CD4 count
<250/mm3) and who were starting treatment with a BMI <18.5.
Exclusion criteria were pregnancy and lactation or participation in
another supplementary feeding programme.”93
ExplanationdA comprehensive description of the eligibility
criteria used to select the trial participants is needed to help readers
interpret the study. In particular, a clear understanding of these
criteria is one of several elements required to judge to whom theresults of a trial applydthat is, the trial’s generalisability (appli-
cability) and relevance to clinical or public health practice (see item
21).94 A description of the method of recruitment, such as by
referral or self selection (for example, through advertisements), is
also important in this context. Because they are applied before
randomisation, eligibility criteria do not affect the internal validity
of a trial, but they are central to its external validity.
Typical and widely accepted selection criteria relate to the
nature and stage of the disease being studied, the exclusion of
persons thought to be particularly vulnerable to harm from the
study intervention, and to issues required to ensure that the study
satisﬁes legal and ethical norms. Informed consent by study
participants, for example, is typically required in intervention
studies. The common distinction between inclusion and exclusion
criteria is unnecessary; the same criterion can be phrased to
include or exclude participants.95
Despite their importance, eligibility criteria are often not re-
ported adequately. For example, eight published trials leading to
clinical alerts by the National Institutes of Health speciﬁed an
average of 31 eligibility criteria in their protocols, but only 63% of
the criteria were mentioned in the journal articles, and only 19%
were mentioned in the clinical alerts.96 Similar deﬁciencies were
found for HIV clinical trials.97 Among 364 reports of RCTs in surgery,
25% did not specify any eligibility criteria.98
5.3.4. Item 4b. Settings and locations where the data were collected
Exampled“The study took place at the antiretroviral therapy
clinic of Queen Elizabeth Central Hospital in Blantyre, Malawi, from
January 2006 to April 2007. Blantyre is themajor commercial city of
Malawi, with a population of 1000 000 and an estimated HIV
prevalence of 27% in adults in 2004.”93
ExplanationdAlong with the eligibility criteria for participants
(see item 4a) and the description of the interventions (see item 5),
information on the settings and locations is crucial to judge the
applicability and generalisability of a trial. Were participants
recruited from primary, secondary, or tertiary healthcare or from
the community? Healthcare institutions vary greatly in their
organisation, experience, and resources and the baseline risk for
the condition under investigation. Other aspects of the setting
(including the social, economic, and cultural environment and the
climate) may also affect a study’s external validity.
Authors should report the number and type of settings and
describe the care providers involved. They should report the loca-
tions inwhich the study was carried out, including the country, city
if applicable, and immediate environment (for example, commu-
nity, ofﬁce practice, hospital clinic, or inpatient unit). In particular, it
should be clear whether the trial was carried out in one or several
centres (“multicentre trials”). This description should provide
enough information so that readers can judge whether the results
of the trial could be relevant to their own setting. The environment
in which the trial is conducted may differ considerably from the
setting in which the trial’s results are later used to guide practice
and policy.94,99 Authors should also report any other information
about the settings and locations that could have inﬂuenced the
observed results, such as problems with transportation that might
have affected patient participation or delays in administering
interventions.
5.3.5. Item 5. The interventions for each group with sufﬁcient
details to allow replication, including how and when they were
actually administered
Examplesd“In POISE, patients received the ﬁrst dose of the
study drug (i.e., oral extended-release metoprolol 100 mg or
matching placebo) 2e4 h before surgery. Study drug administration
required a heart rate of 50 bpm or more and a systolic blood
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checked before each administration. If, at any time during the ﬁrst
6 h after surgery, heart rate was 80 bpm or more and systolic blood
pressure was 100 mm Hg or higher, patients received their ﬁrst
postoperative dose (extended-release metoprolol 100 mg or
matched placebo) orally. If the study drug was not given during the
ﬁrst 6 h, patients received their ﬁrst postoperative dose at 6 h after
surgery. 12 h after the ﬁrst postoperative dose, patients started
taking oral extended-release metoprolol 200 mg or placebo every
day for 30 days. If a patient’s heart rate was consistently below
45 bpm or their systolic blood pressure dropped below 100mmHg,
study drug was withheld until their heart rate or systolic blood
pressure recovered; the study drug was then restarted at 100 mg
once daily. Patients whose heart rate was consistently 45e49 bpm
and systolic blood pressure exceeded 100 mm Hg delayed taking
the study drug for 12 h”.100
“Patients were randomly assigned to receive a custom-made
neoprene splint to be worn at night or to usual care. The splint
was a rigid rest orthosis recommended for use only at night. It
covered the base of the thumb and the thenar eminence but not the
wrist (Fig. 1). Splints were made by 3 trained occupational thera-
pists, who adjusted the splint for each patient so that the ﬁrst web
could be opened and the thumb placed in opposition with the ﬁrst
long ﬁnger. Patients were encouraged to contact the occupational
therapist if they felt that the splint needed adjustment, pain
increased while wearing the splint, or they had adverse effects
(such as skin erosion). Because no treatment can be considered the
gold standard in this situation, patients in the control and inter-
vention groups received usual care at the discretion of their
physician (general practitioner or rheumatologist). We decided not
to use a placebo because, to our knowledge, no placebo for splinting
has achieved successful blinding of patients, as recommended.”101
ExplanationdAuthors should describe each intervention thor-
oughly, including control interventions. The description should
allow a clinician wanting to use the intervention to know exactly
how to administer the intervention that was evaluated in the
trial.102 For a drug intervention, information would include the
drug name, dose, method of administration (such as oral, intrave-
nous), timing and duration of administration, conditions under
which interventions are withheld, and titration regimen if appli-
cable. If the control group is to receive “usual care” it is important to
describe thoroughly what that constitutes. If the control group or
intervention group is to receive a combination of interventions the
authors should provide a thorough description of each interven-
tion, an explanation of the order in which the combination of
interventions are introduced or withdrawn, and the triggers for
their introduction if applicable.
Speciﬁc extensions of the CONSORT statement address the
reporting of non-pharmacologic and herbal interventions and their
particular reporting requirements (such as expertise, details of how
the interventions were standardised).43,44 We recommend readers
consult the statements for non-pharmacologic and herbal inter-
ventions as appropriate.
5.3.6. Item 6a. Completely deﬁned pre-speciﬁed primary and
secondary outcome measures, including how and when they were
assessed
Exampled“The primary endpoint with respect to efﬁcacy in
psoriasis was the proportion of patients achieving a 75% improve-
ment in psoriasis activity from baseline to 12weeks as measured by
the PASI [psoriasis area and severity index] Additional analyses
were done on the percentage change in PASI scores and improve-
ment in target psoriasis lesions.”103
ExplanationdAll RCTs assess response variables, or outcomes
(endpoints), for which the groups are compared. Most trials haveseveral outcomes, some of which are of more interest than others.
The primary outcome measure is the pre-speciﬁed outcome
considered to be of greatest importance to relevant stakeholders
(such a patients, policy makers, clinicians, funders) and is usually
the one used in the sample size calculation (see item 7). Some trials
may have more than one primary outcome. Having several primary
outcomes, however, incurs the problems of interpretation associ-
ated with multiplicity of analyses (see items 18 and 20) and is not
recommended. Primary outcomes should be explicitly indicated as
such in the report of an RCT. Other outcomes of interest are
secondary outcomes (additional outcomes). There may be several
secondary outcomes, which often include unanticipated or unin-
tended effects of the intervention (see item 19), although harms
should always be viewed as important whether they are labelled
primary or secondary.
All outcome measures, whether primary or secondary, should
be identiﬁed and completely deﬁned. The principle here is that the
information provided should be sufﬁcient to allow others to use the
same outcomes.102 When outcomes are assessed at several time
points after randomisation, authors should also indicate the pre-
speciﬁed time point of primary interest. For many non-
pharmacological interventions it is helpful to specify who
assessed outcomes (for example, if special skills are required to do
so) and how many assessors there were.43
Where available and appropriate, the use of previously devel-
oped and validated scales or consensus guidelines should be re-
ported,104,105 both to enhance quality of measurement and to assist
in comparison with similar studies.106 For example, assessment of
quality of life is likely to be improved by using a validated instru-
ment.107 Authors should indicate the provenance and properties of
scales.
More than 70 outcomes were used in 196 RCTs of non-steroidal
anti-inﬂammatory drugs for rheumatoid arthritis,108 and 640
different instruments had been used in 2000 trials in schizo-
phrenia, of which 369 had been used only once.33 Investigation of
149 of those 2000 trials showed that unpublished scales were
a source of bias. In non-pharmacological trials, a third of the claims
of treatment superiority based on unpublished scales would not
have been made if a published scale had been used.109 Similar data
have been reported elsewhere.110,111 Only 45% of a cohort of 519
RCTs published in 2000 speciﬁed the primary outcome16; this
compares with 53% for a similar cohort of 614 RCTs published in
2006.17
5.3.7. Item 6b. Any changes to trial outcomes after the trial
commenced, with reasons
Exampled“The original primary endpoint was all-cause
mortality, but, during a masked analysis, the data and safety
monitoring board noted that overall mortality was lower than had
been predicted and that the study could not be completed with the
sample size and power originally planned. The steering committee
therefore decided to adopt co-primary endpoints of all-cause
mortality (the original primary endpoint), together with all-cause
mortality or cardiovascular hospital admissions (the ﬁrst pre-
speciﬁed secondary endpoint).”112
ExplanationdThere are many reasons for departures from the
initial study protocol (see item 24). Authors should report all major
changes to the protocol, including unplanned changes to eligibility
criteria, interventions, examinations, data collection, methods of
analysis, and outcomes. Such information is not always reported.
As indicated earlier (see item 6a), most trials record multiple
outcomes, with the risk that results will be reported for only
a selected subset (see item 17). Pre-speciﬁcation and reporting of
primary and secondary outcomes (see item 6a) should remove such
a risk. In some trials, however, circumstances require a change in
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a switch to a different outcome. For example, there may be external
evidence from other trials or systematic reviews suggesting the
endpoint might not be appropriate, or recruitment or the overall
event rate in the trial may be lower than expected.112 Changing an
endpoint based on unblinded data is much more problematic,
although it may be speciﬁed in the context of an adaptive trial
design.88 Authors should identify and explain any such changes.
Likewise, any changes after the trial began of the designation of
outcomes as primary or secondary should be reported and
explained.
A comparison of protocols and publications of 102 randomised
trials found that 62% of trials reports had at least one primary
outcome that was changed, introduced, or omitted compared with
the protocol.55 Primary outcomes also differed between protocols
and publications for 40% of a cohort of 48 trials funded by the
Canadian Institutes of Health Research.113 Not one of the subse-
quent 150 trial reports mentioned, let alone explained, changes
from the protocol. Similar results from other studies have been
reported recently in a systematic review of empirical studies
examining outcome reporting bias.57
5.3.8. Item 7a. How sample size was determined
Examplesd“To detect a reduction in PHS (postoperative
hospital stay) of 3 days (SD 5 days), which is in agreement with the
study of Lobo et al.17 with a two-sided 5% signiﬁcance level and
a power of 80%, a sample size of 50 patients per group was
necessary, given an anticipated dropout rate of 10%. To recruit this
number of patients a 12-month inclusion period was
anticipated.”114
“Based on an expected incidence of the primary composite
endpoint of 11% at 2.25 years in the placebo group, we calculated
that wewould need 950 primary endpoint events and a sample size
of 9650 patients to give 90% power to detect a signiﬁcant difference
between ivabradine and placebo, corresponding to a 19% reduction
of relative risk (with a two-sided type 1 error of 5%). We initially
designed an event-driven trial, and planned to stop when 950
primary endpoint events had occurred. However, the incidence of
the primary endpoint was higher than predicted, perhaps because
of baseline characteristics of the recruited patients, who had higher
risk than expected (e.g., lower proportion of NYHA class I and
higher rates of diabetes and hypertension). We calculated that
when 950 primary endpoint events had occurred, themost recently
included patients would only have been treated for about 3months.
Therefore, in January 2007, the executive committee decided to
change the study from being event-driven to time-driven, and to
continue the study until the patients who were randomised last
had been followed up for 12 months. This change did not alter the
planned study duration of 3 years.”115
ExplanationdFor scientiﬁc and ethical reasons, the sample size
for a trial needs to be planned carefully, with a balance between
medical and statistical considerations. Ideally, a study should be
large enough to have a high probability (power) of detecting as
statistically signiﬁcant a clinically important difference of a given
size if such a difference exists. The size of effect deemed important
is inversely related to the sample size necessary to detect it; that is,
large samples are necessary to detect small differences. Elements of
the sample size calculation are (1) the estimated outcomes in each
group (which implies the clinically important target difference
between the intervention groups); (2) the a (type I) error level; (3)
the statistical power (or the b (type II) error level); and (4), for
continuous outcomes, the standard deviation of the measure-
ments.116 The interplay of these elements and their reporting will
differ for cluster trials40 and non-inferiority and equivalence
trials.39Authors should indicate how the sample size was determined. If
a formal power calculation was used, the authors should identify
the primary outcome onwhich the calculation was based (see item
6a), all the quantities used in the calculation, and the resulting
target sample size per study group. It is preferable to quote the
expected result in the control group and the difference between the
groups one would not like to overlook. Alternatively, authors could
present the percentage with the event or mean for each group used
in their calculations. Details should be given of any allowance made
for attrition or non-compliance during the study.
Somemethodologists havewritten that so called underpowered
trials may be acceptable because they could ultimately be
combined in a systematic review and meta-analysis,117e119 and
because some information is better than no information. Of note,
important caveats applydsuch as the trial should be unbiased,
reported properly, and published irrespective of the results,
thereby becoming available formeta-analysis.118 On the other hand,
many medical researchers worry that underpowered trials with
indeterminate results will remain unpublished and insist that all
trials should individually have “sufﬁcient power.” This debate will
continue, and members of the CONSORT Group have varying views.
Critically however, the debate and those views are immaterial to
reporting a trial. Whatever the power of a trial, authors need to
properly report their intended size with all their methods and
assumptions.118 That transparently reveals the power of the trial to
readers and gives them a measure by which to assess whether the
trial attained its planned size.
In some trials, interim analyses are used to help decide whether
to stop early or to continue recruiting sometimes beyond the
planned trial end (see item 7b). If the actual sample size differed
from the originally intended sample size for some other reason (for
example, because of poor recruitment or revision of the target
sample size), the explanation should be given.
Reports of studies with small samples frequently include the
erroneous conclusion that the intervention groups do not differ,
when in fact too few patients were studied to make such a claim.120
Reviews of published trials have consistently found that a high
proportion of trials have low power to detect clinically meaningful
treatment effects.121e123 In reality, small but clinically meaningful
true differences are much more likely than large differences to
exist, but large trials are required to detect them.124
In general, the reported sample sizes in trials seem small. The
median sample size was 54 patients in 196 trials in arthritis,108 46
patients in 73 trials in dermatology,8 and 65 patients in 2000 trials
in schizophrenia.33 These small sample sizes are consistent with
those of a study of 519 trials indexed in PubMed in December
200016 and a similar cohort of trials (n¼ 616) indexed in PubMed in
2006,17 where the median number of patients recruited for parallel
group trials was 80 across both years. Moreover, many reviews have
found that few authors report how they determined the sample
size.8,14,32,33,123
There is little merit in a post hoc calculation of statistical power
using the results of a trial; the power is then appropriately indi-
cated by conﬁdence intervals (see item 17).125
5.3.9. Item 7b. When applicable, explanation of any interim
analyses and stopping guidelines
Examplesd“Two interim analyses were performed during the
trial. The levels of signiﬁcance maintained an overall P value of 0.05
and were calculated according to the O’Brien-Fleming stopping
boundaries. This ﬁnal analysis used a Z score of 1.985 with an
associated P value of 0.0471.”126
“An independent data and safety monitoring board periodically
reviewed the efﬁcacy and safety data. Stopping rules were based on
modiﬁed Haybittle-Peto boundaries of 4 SD in the ﬁrst half of the
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ﬁrst half of the study and 2 SD in the second half for safety data.
Two formal interim analyses of efﬁcacy were performed when 50%
and 75% of the expected number of primary events had accrued; no
correction of the reported P value for these interim tests was
performed.”127
ExplanationdMany trials recruit participants over a long
period. If an intervention is working particularly well or badly, the
study may need to be ended early for ethical reasons. This concern
can be addressed by examining results as the data accumulate,
preferably by an independent data monitoring committee.
However, performing multiple statistical examinations of accu-
mulating datawithout appropriate correction can lead to erroneous
results and interpretations.128 If the accumulating data from a trial
are examined at ﬁve interim analyses that use a P value of 0.05, the
overall false positive rate is nearer to 19% than to the nominal 5%.
Several group sequential statistical methods are available to
adjust for multiple analyses,129e131 and their use should be pre-
speciﬁed in the trial protocol. With these methods, data are
compared at each interim analysis, and a P value less than the
critical value speciﬁed by the group sequential method indicates
statistical signiﬁcance. Some trialists use group sequential methods
as an aid to decision making,132 whereas others treat them as
a formal stopping rule (with the intention that the trial will cease if
the observed P value is smaller than the critical value).
Authors should report whether they or a data monitoring
committee took multiple “looks” at the data and, if so, how many
there were, what triggered them, the statistical methods used
(including any formal stopping rule), and whether they were
planned before the start of the trial, before the data monitoring
committee saw any interim data by allocation, or some time
thereafter. This information is often not included in published trial
reports,133 even in trials that report stopping earlier than
planned.134
5.3.10. Item 8a. Method used to generate the random allocation
sequence
Examplesd“Independent pharmacists dispensed either active
or placebo inhalers according to a computer-generated random-
isation list.”63
“For allocation of the participants, a computer-generated list of
random numbers was used.”135
ExplanationdParticipants should be assigned to comparison
groups in the trial on the basis of a chance (random) process
characterised by unpredictability (see Box 1). Authors should
provide sufﬁcient information that the reader can assess the
methods used to generate the random allocation sequence and the
likelihood of bias in group assignment. It is important that infor-
mation on the process of randomisation is included in the body of
the main article and not as a separate supplementary ﬁle; where it
can be missed by the reader.
The term “random” has a precise technical meaning. With
random allocation, each participant has a known probability of
receiving each intervention before one is assigned, but the assigned
intervention is determined by a chance process and cannot be
predicted. However, “random” is often used inappropriately in the
literature to describe trials in which non-random, deterministic
allocation methods were used, such as alternation, hospital
numbers, or date of birth. When investigators use such non-
random methods, they should describe them precisely and
should not use the term “random” or any variation of it. Even the
term “quasi-random” is unacceptable for describing such trials.
Trials based on non-random methods generally yield biased
results.2e4,136 Bias presumably arises from the inability to conceal
these allocation systems adequately (see item 9).Many methods of sequence generation are adequate. However,
readers cannot judge adequacy from such terms as “random alloca-
tion,” “randomisation,” or “random” without further elaboration.
Authors should specify the method of sequence generation, such as
a random-number tableora computerised randomnumbergenerator.
Thesequencemaybegeneratedby theprocessofminimisation, anon-
random but generally acceptable method (see Box 2).
In some trials, participants are intentionally allocated in unequal
numbers to each intervention: for example, to gain more experience
with a new procedure or to limit costs of the trial. In such cases,
authors should report the randomisation ratio (for example, 2:1 or
twotreatmentparticipantspereachcontrolparticipant) (see item3a).
In a representative sample of PubMed indexed trials in 2000,
only 21% reported an adequate approach to random sequence
generation16; this increased to 34% for a similar cohort of PubMed
indexed trials in 2006.17 In more than 90% of these cases,
researchers used a random number generator on a computer or
a random number table.
5.3.11. Item 8b. Type of randomisation; details of any restriction
(such as blocking and block size)
Examplesd“Randomization sequence was created using Stata
9.0 (StataCorp, College Station, TX) statistical software and was
stratiﬁed by center with a 1:1 allocation using random block sizes
of 2, 4, and 6.”137
“Participants were randomly assigned following simple
randomization procedures (computerized random numbers) to 1 of
2 treatment groups.”138
ExplanationdIn trials of several hundred participants or more
simple randomisation can usually be trusted to generate similar
numbers in the two trial groups139 and to generate groups that are
roughly comparable in terms of known and unknown prognostic
variables.140 For smaller trials (see item 7a)dand even for trials that
are not intended to be small, as theymay stop before reaching their
target sizedsome restricted randomisation (procedures to help
achieve balance between groups in size or characteristics) may be
useful (see Box 2).
It is important to indicate whether no restriction was used, by
stating such or by stating that “simple randomisation” was done.
Otherwise, the methods used to restrict the randomisation, along
with the method used for random selection, should be speciﬁed.
For block randomisation, authors should provide details on how the
blocks were generated (for example, by using a permuted block
design with a computer random number generator), the block size
or sizes, and whether the block size was ﬁxed or randomly varied. If
the trialists became aware of the block size(s), that information
should also be reported as such knowledge could lead to code
breaking. Authors should specify whether stratiﬁcation was used,
and if so, which factors were involved (such as recruitment site, sex,
disease stage), the categorisation cut-off values within strata, and
the method used for restriction. Although stratiﬁcation is a useful
technique, especially for smaller trials, it is complicated to imple-
ment and may be impossible if many stratifying factors are used. If
minimisation (see Box 2) was used, it should be explicitly identi-
ﬁed, as should the variables incorporated into the scheme. If used,
a random element should be indicated.
Only 9% of 206 reports of trials in specialty journals23 and 39% of
80 trials in general medical journals reported use of stratiﬁcation.32
In each case, only about half of the reports mentioned the use of
restricted randomisation. However, these studies and that of Ade-
tugbo andWilliams8 found that the sizes of the treatment groups in
many trials were the same or quite similar, yet blocking or strati-
ﬁcation had not been mentioned. One possible explanation for the
close balance in numbers is underreporting of the use of restricted
randomisation.
Box 2. Randomisation and minimisation
 Simple randomisationdPure randomisation based on
a single allocation ratio is known as simple random-
isation. Simple randomisationwith a 1:1 allocation ratio
is analogous to a coin toss, althoughwedonot advocate
coin tossing for randomisation in an RCT. “Simple” is
somewhat of a misnomer. While other randomisation
schemes sound complex and more sophisticated, in
reality, simple randomisation is elegantly sophisticated
in that it is more unpredictable and surpasses the bias
prevention levels of all other alternatives.
 Restricted randomisationdAny randomised approach
that is not simple randomisation. Blocked random-
isation is the most common form. Other means of
restricted randomisation include replacement, biased
coin, and urn randomisation, although these are used
much less frequently.141
 Blocked randomisationdBlocking is used to ensure
that comparison groups will be generated according to
a predetermined ratio, usually 1:1 or groups of
approximately the same size. Blocking can be used to
ensure close balance of the numbers in each group at
any time during the trial. For every block of eight
participants, for example, four would be allocated to
each arm of the trial.142 Improved balance comes at the
cost of reducing the unpredictability of the sequence.
Although the order of interventions varies randomly
within each block, a person running the trial could
deduce some of the next treatment allocations if he or
she knew the block size.143 Blinding the interventions,
using larger block sizes, and randomly varying the
block size can ameliorate this problem.
 Stratified randomisationdStratification is used to
ensure good balance of participant characteristics in
each group. By chance, particularly in small trials, study
groups may not be well matched for baseline charac-
teristics, such as age and stage of disease. This
weakens the trial’s credibility.144 Such imbalances can
be avoided without sacrificing the advantages of ran-
domisation. Stratification ensures that the numbers of
participants receiving each intervention are closely
balanced within each stratum. Stratified randomisation
is achieved by performing a separate randomisation
procedure within each of two or more subsets of
participants (for example, those defining each study
centre, age, or disease severity). Stratification by centre
is common in multicentre trials. Stratification requires
some form of restriction (such as blocking within
strata). Stratification without blocking is ineffective.
 MinimisationdMinimisation ensures balance between
intervention groups for several selected patient factors
(such as age).22,60 The first patient is truly randomly
allocated; for each subsequent participant, the treat-
ment allocation that minimises the imbalance on the
selected factors between groups at that time is identi-
fied. That allocation may then be used, or a choice may
be made at random with a heavy weighting in favour of
the intervention that would minimise imbalance (for
example, with a probability of 0.8). The use of a random
component is generally preferable. Minimisation has
the advantage of making small groups closely similar in
terms of participant characteristics at all stages of the
trial. Minimisation offers the only acceptable alternative
to randomisation, and some have argued that it is
superior.145 On the other hand, minimisation lacks the
theoretical basis for eliminating bias on all known and
unknown factors. Nevertheless, in general, trials that
use minimisation are considered methodologically
equivalent to randomised trials, even when a random
element is not incorporated.
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allocation sequence (such as sequentially numbered containers),
describing any steps taken to conceal the sequence until
interventions were assigned
Examplesd“The doxycycline and placebo were in capsule form
and identical in appearance. They were prepacked in bottles and
consecutively numbered for each woman according to the ran-
domisation schedule. Each woman was assigned an order number
and received the capsules in the corresponding prepacked
bottle.”146
“The allocation sequencewas concealed from the researcher (JR)
enrolling and assessing participants in sequentially numbered,
opaque, sealed and stapled envelopes. Aluminium foil inside the
envelope was used to render the envelope impermeable to intense
light. To prevent subversion of the allocation sequence, the name
and date of birth of the participant was written on the envelope and
a video tape made of the sealed envelope with participant details
visible. Carbon paper inside the envelope transferred the infor-
mation onto the allocation card inside the envelope and a second
researcher (CC) later viewed video tapes to ensure envelopes were
still sealed when participants’ names were written on them. Cor-
responding envelopes were opened only after the enrolled partic-
ipants completed all baseline assessments and it was time to
allocate the intervention.”147
ExplanationdItem 8a discussed generation of an unpredictable
sequence of assignments. Of considerable importance is how this
sequence is applied when participants are enrolled into the trial
(see Box 1). A generated allocation schedule should be imple-
mented by using allocation concealment,23 a critical mechanism
that prevents foreknowledge of treatment assignment and thus
shields those who enroll participants from being inﬂuenced by this
knowledge. The decision to accept or reject a participant should be
made, and informed consent should be obtained from the partici-
pant, in ignorance of the next assignment in the sequence.148
Theallocationconcealment shouldnot beconfusedwithblinding
(see item 11). Allocation concealment seeks to prevent selection
bias, protects the assignment sequence until allocation, and can
always be successfully implemented.2 In contrast, blinding seeks to
prevent performance and ascertainment bias, protects the sequence
after allocation, and cannot always be implemented.23 Without
adequate allocation concealment, however, even random, unpre-
dictable assignment sequences can be subverted.2,149
Centralised or “third-party” assignment is especially desirable.
Many good allocation concealment mechanisms incorporate
external involvement. Use of a pharmacy or central telephone
randomisation system are two common techniques. Automated
assignment systems are likely to become more common.150 When
external involvement is not feasible, an excellent method of allo-
cation concealment is the use of numbered containers. The inter-
ventions (often drugs) are sealed in sequentially numbered
identical containers according to the allocation sequence.151
Enclosing assignments in sequentially numbered, opaque, sealed
envelopes can be a good allocation concealment mechanism if it is
developed andmonitored diligently. This method can be corrupted,
however, particularly if it is poorly executed. Investigators should
ensure that the envelopes are opaque when held to the light, and
opened sequentially and only after the participant’s name and
other details are written on the appropriate envelope.143
A number of methodological studies provide empirical evidence
to support these precautions.152,153 Trials in which the allocation
sequence had been inadequately or unclearly concealed yielded
larger estimates of treatment effects than did trials in which
authors reported adequate allocation concealment. These ﬁndings
provide strong empirical evidence that inadequate allocation
concealment contributes to bias in estimating treatment effects.
Box 3. Steps in a typical randomisation process
Sequence generation
 Generate allocation sequence by some random
procedure
Allocation concealment
 Develop allocation concealmentmechanism (such as
numbered, identical bottles or sequentially
numbered, sealed, opaque envelopes)
 Prepare the allocation concealment mechanism
using the allocation sequence from the sequence
generation step
Implementation
 Enrol participants:
B Assess eligibility
B Discuss the trial
B Obtain informed consent
B Enrol participant in trial
 Ascertain intervention assignment (such as opening
next envelope)
 Administer intervention
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concealment, published reports often omit such details. The
mechanism used to allocate interventions was omitted in reports of
89% of trials in rheumatoid arthritis,108 48% of trials in obstetrics
and gynaecology journals,23 and 44% of trials in general medical
journals.32 In a more broadly representative sample of all rando-
mised trials indexed on PubMed, only 18% reported any allocation
concealment mechanism, but some of those reported mechanisms
were inadequate.16
5.3.13. Item 10. Who generated the allocation sequence, who
enrolled participants, and who assigned participants to
interventions
Examplesd“Determination of whether a patient would be
treated by streptomycin and bed-rest (S case) or by bed-rest alone
(C case) was made by reference to a statistical series based on
random sampling numbers drawn up for each sex at each centre by
Professor Bradford Hill; the details of the series were unknown to
any of the investigators or to the coordinator. After acceptance of
a patient by the panel, and before admission to the streptomycin
centre, the appropriate numbered envelope was opened at the
central ofﬁce; the card inside told if the patient was to be an S or a C
case, and this information was then given to the medical ofﬁcer of
the centre.”24
“Details of the allocated group were given on coloured cards
contained in sequentially numbered, opaque, sealed envelopes.
These were prepared at the NPEU and kept in an agreed location on
each ward. Randomisation took place at the end of the 2nd stage of
labour when the midwife considered a vaginal birth was imminent.
To enter a women into the study, the midwife opened the next
consecutively numbered envelope.”154
“Block randomisation was by a computer-generated random
number list prepared by an investigator with no clinical involve-
ment in the trial. We stratiﬁed by admission for an oncology related
procedure. After the research nurse had obtained the patient’s
consent, she telephoned a contact who was independent of the
recruitment process for allocation consignment.”155
ExplanationdAs noted in item 9, concealment of the allocated
intervention at the time of enrolment is especially important. Thus,
in addition to knowing the methods used, it is also important to
understand how the random sequence was implementeddspe-
ciﬁcally, who generated the allocation sequence, who enrolled
participants, and who assigned participants to trial groups.
The process of randomising participants into a trial has three
different steps: sequence generation, allocation concealment, and
implementation (see Box 3). Although the same people may carry
out more than one process under each heading, investigators
should strive for complete separation of the people involved with
generation and allocation concealment from the people involved in
the implementation of assignments. Thus, if someone is involved in
the sequence generation or allocation concealment steps, ideally
they should not be involved in the implementation step.
Even with ﬂawless sequence generation and allocation
concealment, failure to separate creation and concealment of the
allocation sequence from assignment to study groupmay introduce
bias. For example, the person who generated an allocation
sequence could retain a copy and consult it when interviewing
potential participants for a trial. Thus, that person could bias the
enrolment or assignment process, regardless of the unpredictability
of the assignment sequence. Investigators must then ensure that
the assignment schedule is unpredictable and locked away (such as
in a safe deposit box in a building rather inaccessible to the
enrolment location) from even the person who generated it. The
report of the trial should specify where the investigators stored the
allocation list.5.3.14. Item 11a. If done, who was blinded after assignment to
interventions (for example, participants, care providers, those
assessing outcomes) and how
Examplesd“Whereas patients and physicians allocated to the
intervention group were aware of the allocated arm, outcome
assessors and data analysts were kept blinded to the allocation.”156
“Blinding and equipoise were strictly maintained by emphasis-
ing to intervention staff and participants that each diet adheres to
healthy principles, and each is advocated by certain experts to be
superior for long-term weight-loss. Except for the interventionists
(dieticians and behavioural psychologists), investigators and staff
were kept blind to diet assignment of the participants. The trial
adhered to established procedures to maintain separation between
staff that take outcome measurements and staff that deliver the
intervention. Staff members who obtained outcomemeasurements
were not informed of the diet group assignment. Intervention staff,
dieticians and behavioural psychologists who delivered the inter-
vention did not take outcome measurements. All investigators,
staff, and participants were kept masked to outcome measure-
ments and trial results.”157
ExplanationdThe term “blinding” or “masking” refers to
withholding information about the assigned interventions from
people involved in the trial who may potentially be inﬂuenced by
this knowledge. Blinding is an important safeguard against bias,
particularly when assessing subjective outcomes.153
Benjamin Franklin has been credited as being the ﬁrst to use
blinding in a scientiﬁc experiment.158 He blindfolded participants
so they would not know when he was applying mesmerism (a
popular “healing ﬂuid” of the 18th century) and in so doing showed
that mesmerism was a sham. Based on this experiment, the
scientiﬁc community recognised the power of blinding to reduce
bias, and it has remained a commonly used strategy in scientiﬁc
experiments.
Box 4, on blinding terminology, deﬁnes the groups of individuals
(that is, participants, healthcare providers, data collectors, outcome
adjudicators, and data analysts) who can potentially introduce bias
into a trial through knowledge of the treatment assignments.
Participants may respond differently if they are aware of their
treatment assignment (such as responding more favourably when
they receive the new treatment).153 Lack of blinding may also
Box 4. Blinding terminology
In order for a technical term to have utility it must have
consistency in its use and interpretation. Authors of trials
commonly use the term “double blind” and, less
commonly, the terms “single blind”or “triple blind.” A
problem with this lexicon is that there is great variability in
clinician interpretations and epidemiological textbook
definitions of these terms.169 Moreover, a study of 200 RCTs
reported as double blind found 18 different combinations of
groups actually blinded when the authors of these trials
were surveyed, and about one in every five of these tri-
alsdreported as double blindddid not blind participants,
healthcare providers, or data collectors.170
This research shows that terms are ambiguous and, as
such, authors and editors should abandon their use.
Authors should instead explicitly report the blinding status
of the people involved for whom blindingmay influence the
validity of a trial.
Healthcare providers include all personnel (for example,
physicians, chiropractors, physiotherapists, nurses) who
care for the participants during the trial. Data collectors are
the individuals who collect data on the trial outcomes.
Outcome adjudicators are the individuals who determine
whether a participant did experience the outcomes of
interest.
Some researchers have also advocated blinding and
reporting the blinding status of the data monitoring
committee and the manuscript writers.160 Blinding of these
groups is uncommon, and the value of blinding them is
debated.171
Sometimes one group of individuals (such as the healthcare
providers) are the same individuals fulfilling another role in
a trial (such as data collectors). Even if this is the case, the
authors should explicitly state the blinding status of these
groups to allow readers to judge the validity of the trial.
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interventions, and risk of dropping out of the trial.
Unblinded healthcare providers may introduce similar biases,
and unblinded data collectors may differentially assess outcomes
(such as frequency or timing), repeat measurements of abnormal
ﬁndings, or provide encouragement during performance testing.
Unblinded outcome adjudicators may differentially assess subjec-
tive outcomes, and unblinded data analysts may introduce bias
through the choice of analytical strategies, such as the selection of
favourable time points or outcomes, and by decisions to remove
patients from the analyses. These biases have been well
documented.71,153,159e162
Blinding, unlike allocation concealment (see item 10), may not
always be appropriate or possible. An example is a trial comparing
levels of pain associated with sampling blood from the ear or
thumb.163 Blinding is particularly important when outcome
measures involve some subjectivity, such as assessment of pain.
Blinding of data collectors and outcome adjudicators is unlikely to
matter for objective outcomes, such as death from any cause. Even
then, however, lack of participant or healthcare provider blinding
can lead to other problems, such as differential attrition.164 In
certain trials, especially surgical trials, blinding of participants and
surgeons is often difﬁcult or impossible, but blinding of data
collectors and outcome adjudicators is often achievable. For
example, lesions can be photographed before and after treatment
and assessed by an external observer.165 Regardless of whether
blinding is possible, authors can and should always state who was
blinded (that is, participants, healthcare providers, data collectors,
and outcome adjudicators).
Unfortunately, authors often do not report whether blinding
was used.166 For example, reports of 51% of 506 trials in cystic
ﬁbrosis,167 33% of 196 trials in rheumatoid arthritis,108 and 38% of
68 trials in dermatology8 did not state whether blinding was used.
Until authors of trials improve their reporting of blinding, readers
will have difﬁculty in judging the validity of the trials that theymay
wish to use to guide their clinical practice.
The term masking is sometimes used in preference to blinding
to avoid confusion with the medical condition of being without
sight. However, “blinding” in its methodological sense seems to be
understood worldwide and is acceptable for reporting clinical
trials.165,168
5.3.15. Item 11b. If relevant, description of the similarity of
interventions
Exampled“Jamieson Laboratories Inc provided 500-mg
immediate release niacin in a white, oblong, bisect caplet. We
independently conﬁrmed caplet content using high performance
liquid chromatography. The placebo was matched to the study
drug for taste, colour, and size, and contained microcrystalline
cellulose, silicon dioxide, dicalcium phosphate, magnesium stea-
rate, and stearic acid.”172
ExplanationdJust as we seek evidence of concealment to
assure us that assignment was truly random, we seek evidence of
the method of blinding. In trials with blinding of participants or
healthcare providers, authors should state the similarity of the
characteristics of the interventions (such as appearance, taste,
smell, and method of administration).35,173
Some people have advocated testing for blinding by asking
participants or healthcare providers at the end of a trial whether
they think the participant received the experimental or control
intervention.174 Because participants and healthcare providers will
usually knowwhether the participant has experienced the primary
outcome, this makes it difﬁcult to determine if their responses
reﬂect failure of blinding or accurate assumptions about the efﬁ-
cacy of the intervention.175 Given the uncertainty this type ofinformation provides, we have removed advocating reporting this
type of testing for blinding from the CONSORT 2010 Statement. We
do, however, advocate that the authors report any known
compromises in blinding. For example, authors should report if it
was necessary to unblind any participants at any point during the
conduct of a trial.
5.3.16. Item 12a. Statistical methods used to compare groups for
primary and secondary outcomes
Exampled“The primary endpoint was change in bodyweight
during the 20 weeks of the study in the intention-to-treat pop-
ulation . Secondary efﬁcacy endpoints included change in waist
circumference, systolic and diastolic blood pressure, prevalence of
metabolic syndrome . We used an analysis of covariance
(ANCOVA) for the primary endpoint and for secondary endpoints
waist circumference, blood pressure, and patient-reported
outcome scores; this was supplemented by a repeated measures
analysis. The ANCOVA model included treatment, country, and sex
as ﬁxed effects, and bodyweight at randomisation as covariate. We
aimed to assess whether data provided evidence of superiority of
each liraglutide dose to placebo (primary objective) and to orlistat
(secondary objective).”176
ExplanationdData can be analysed in many ways, some of
which may not be strictly appropriate in a particular situation. It is
essential to specify which statistical procedure was used for each
analysis, and further clariﬁcation may be necessary in the results
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statistical methods with enough detail to enable a knowledgeable
readerwith access to the original data to verify the reported results”
(www.icmje.org). It is also important to describe details of the
statistical analysis such as intention-to-treat analysis (see Box 6).
Almost all methods of analysis yield an estimate of the treat-
ment effect, which is a contrast between the outcomes in the
comparison groups. Authors should accompany this by a conﬁ-
dence interval for the estimated effect, which indicates a central
range of uncertainty for the true treatment effect. The conﬁdence
interval may be interpreted as the range of values for the treatment
effect that is compatible with the observed data. It is customary to
present a 95% conﬁdence interval, which gives the range expected
to include the true value in 95 of 100 similar studies.
Study ﬁndings can also be assessed in terms of their statistical
signiﬁcance. The P value represents the probability that the
observed data (or a more extreme result) could have arisen by
chance when the interventions did not truly differ. Actual P values
(for example, P ¼ 0.003) are strongly preferable to imprecise
threshold reports such as P < 0.05.48,177
Standard methods of analysis assume that the data are “inde-
pendent.” For controlled trials, this usually means that there is one
observation per participant. Treating multiple observations from
one participant as independent data is a serious error; such data are
producedwhen outcomes can bemeasured on different parts of the
body, as in dentistry or rheumatology. Data analysis should be
based on counting each participant once178,179 or should be done by
using more complex statistical procedures.180 Incorrect analysis of
multiple observations per individual was seen in 123 (63%) of 196
trials in rheumatoid arthritis.108
5.3.17. Item 12b. Methods for additional analyses, such as subgroup
analyses and adjusted analyses
Examplesd“Proportions of patients responding were
compared between treatment groups with the Mantel-Haenszel c2
test, adjusted for the stratiﬁcation variable, methotrexate use.”103
“Pre-speciﬁed subgroup analyses according to antioxidant
treatment assignment(s), presence or absence of prior CVD, dietary
folic acid intake, smoking, diabetes, aspirin, hormone therapy, and
multivitamin use were performed using stratiﬁed Cox proportional
hazards models. These analyses used baseline exposure assess-
ments and were restricted to participants with nonmissing
subgroup data at baseline.”181
ExplanationdAs is the case for primary analyses, the method of
subgroup analysis should be clearly speciﬁed. The strongest anal-
yses are those that look for evidence of a difference in treatment
effect in complementary subgroups (for example, older and
younger participants), a comparison known as a test of interac-
tion.182,183 A common but misleading approach is to compare P
values for separate analyses of the treatment effect in each group. It
is incorrect to infer a subgroup effect (interaction) from one
signiﬁcant and one non-signiﬁcant P value.184 Such inferences have
a high false positive rate.
Because of the high risk for spurious ﬁndings, subgroup analyses
are often discouraged.14,185 Post hoc subgroup comparisons (anal-
yses done after looking at the data) are especially likely not to be
conﬁrmed by further studies. Such analyses do not have great
credibility.
In some studies, imbalances in participant characteristics are
adjusted for by using some form of multiple regression analysis.
Although the need for adjustment is much less in RCTs than in
epidemiological studies, an adjusted analysis may be sensible,
especially if one or more variables is thought to be prognostic.186
Ideally, adjusted analyses should be speciﬁed in the study
protocol (see item 24). For example, adjustment is oftenrecommended for any stratiﬁcation variables (see item 8b) on the
principle that the analysis strategy should follow the design. In
RCTs, the decision to adjust should not be determined by whether
baseline differences are statistically signiﬁcant (see item 16).183,187
The rationale for any adjusted analyses and the statistical
methods used should be speciﬁed.
Authors should clarify the choice of variables that were adjusted
for, indicate how continuous variables were handled, and specify
whether the analysis was planned or suggested by the data.188
Reviews of published studies show that reporting of adjusted
analyses is inadequate with regard to all of these aspects.188e191
5.4. Results
5.4.1. Item 13. Participant ﬂow (a diagram is strongly
recommended)
5.4.1.1. Item 13a. For each group, the numbers of participants who
were randomly assigned, received intended treatment, and were
analysed for the primary outcome. ExamplesdSee Figs 2 and 3.
ExplanationdThe design and conduct of some RCTs is
straightforward, and the ﬂow of participants, particularly were
there are no losses to follow-up or exclusions, through each phase
of the study can be described adequately in a few sentences. In
more complex studies, it may be difﬁcult for readers to discern
whether and why some participants did not receive the treatment
as allocated, were lost to follow-up, or were excluded from the
analysis.51 This information is crucial for several reasons. Partici-
pants who were excluded after allocation are unlikely to be
representative of all participants in the study. For example, patients
may not be available for follow-up evaluation because they expe-
rienced an acute exacerbation of their illness or harms of
treatment.22,192
Attrition as a result of loss to follow-up, which is often
unavoidable, needs to be distinguished from investigator-
determined exclusion for such reasons as ineligibility, withdrawal
from treatment, and poor adherence to the trial protocol. Erroneous
conclusions can be reached if participants are excluded from
analysis, and imbalances in such omissions between groupsmay be
especially indicative of bias.192e194 Information about whether the
investigators included in the analysis all participants who under-
went randomisation, in the groups to which they were originally
allocated (intention-to-treat analysis (see item 16 and Box 6)), is
therefore of particular importance. Knowing the number of
participants who did not receive the intervention as allocated or
did not complete treatment permits the reader to assess to what
extent the estimated efﬁcacy of therapy might be underestimated
in comparison with ideal circumstances.
If available, the number of people assessed for eligibility should
also be reported. Although this number is relevant to external
validity only and is arguably less important than the other
counts,195 it is a useful indicator of whether trial participants were
likely to be representative of all eligible participants.
A review of RCTs published in ﬁve leading general and internal
medicine journals in 1998 found that reporting of the ﬂow of
participants was often incomplete, particularly with regard to the
number of participants receiving the allocated intervention and the
number lost to follow-up.51 Even information as basic as the
number of participants who underwent randomisation and the
number excluded from analyses was not available in up to 20% of
articles.51 Reporting was considerably more thorough in articles
that included a diagram of the ﬂow of participants through a trial,
as recommended by CONSORT. This study informed the design of
the revised ﬂow diagram in the revised CONSORT statement.52e54
The suggested template is shown in Fig. 1, and the counts
required are described in detail in Table 3.
Fig. 2. Flow diagram of a multicentre trial of fractional ﬂow reserve versus angiography for guiding percutaneous coronary intervention (PCI) (adapted from Tonino et al.313). The
diagram includes detailed information on the excluded participants.
Fig. 3. Flow diagram of minimal surgery compared with medical management for chronic gastro-oesophageal reﬂux disease (adapted from Grant et al.196). The diagram shows
a multicentre trial with a parallel non-randomised preference group.
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for eligibility, may not always be known,14 and, depending on the
nature of a trial, some counts may be more relevant than others. It
will sometimes be useful or necessary to adapt the structure of the
ﬂow diagram to a particular trial. In some situations, other infor-
mation may usefully be added. For example, the ﬂow diagram of
a parallel group trial of minimal surgery compared with medical
management for chronic gastro-oesophageal reﬂux also included
a parallel non-randomised preference group (see Fig. 3).196
The exact form and content of the ﬂow diagram may be varied
according to speciﬁc features of a trial. For example, many trials of
surgery or vaccination do not include the possibility of discontin-
uation. Although CONSORT strongly recommends using this
graphical device to communicate participant ﬂow throughout the
study, there is no speciﬁc, prescribed format.
5.4.1.2. Item 13b. For each group, losses and exclusions after ran-
domisation, together with reasons. Examplesd“There was only one
protocol deviation, in a woman in the study group. She had an
abnormal pelvic measurement and was scheduled for elective
caesarean section. However, the attending obstetrician judged
a trial of labour acceptable; caesarean sectionwas done when there
was no progress in the ﬁrst stage of labour.”197
“The monitoring led to withdrawal of nine centres, in which
existence of some patients could not be proved, or other serious
violations of good clinical practice had occurred.”198
ExplanationdSome protocol deviations may be reported in the
ﬂow diagram (see item 13a)dfor example, participants who did not
receive the intended intervention. If participants were excluded
after randomisation (contrary to the intention-to-treat principle)
because they were found not to meet eligibility criteria (see item
16), they should be included in the ﬂow diagram. Use of the term
“protocol deviation” in published articles is not sufﬁcient to justify
exclusion of participants after randomisation. The nature of the
protocol deviation and the exact reason for excluding participants
after randomisation should always be reported.
5.4.2. Item 14a. Dates deﬁning the periods of recruitment and
follow-up
Exampled“Age-eligible participants were recruited . from
February 1993 to September 1994 . Participants attended clinic
visits at the time of randomisation (baseline) and at 6-month
intervals for 3 years.”199Table 3
Information required to document the ﬂow of participants through each stage of a rand
Stage Number of people included Number of people
Enrolment People evaluated for
potential enrolment
People who did no
criteria or met the
declined to be enro
Randomisation Participants randomly assigned
Treatment
allocation
Participants who received treatment
as allocated, by study group
Participants who d
as allocated, by stu
Follow-up Participants who completed treatment
as allocated, by study group
Participants who d
as allocated, by stu
Participants who completed follow-up
as planned, by study group
Participants who d
as planned, by stud
Analysis Participants included in main analysis,
by study group
Participants exclud
analysis, by study gExplanationdKnowing when a study took place and over what
period participants were recruited places the study in historical
context. Medical and surgical therapies, including concurrent
therapies, evolve continuously and may affect the routine care
given to participants during a trial. Knowing the rate at which
participants were recruited may also be useful, especially to other
investigators.
The length of follow-up is not always a ﬁxed period after ran-
domisation. In many RCTs inwhich the outcome is time to an event,
follow-up of all participants is ended on a speciﬁc date. This date
should be given, and it is also useful to report the minimum,
maximum, and median duration of follow-up.200,201
A review of reports in oncology journals that used survival
analysis, most of which were not RCTs,201 found that nearly 80%
(104 of 132 reports) included the starting and ending dates for
accrual of patients, but only 24% (32 of 132 reports) also reported
the date on which follow-up ended.
5.4.3. Item 14b. Why the trial ended or was stopped
Examplesd“At the time of the interim analysis, the total follow-
up included an estimated 63% of the total number of patient-years
that would have been collected at the end of the study, leading to
a threshold value of 0.0095, as determined by the Lan-DeMets
alpha-spending function method . At the interim analysis, the
RR was 0.37 in the intervention group, as compared with the
control group, with a p value of 0.00073, below the threshold value.
The Data and Safety Monitoring Board advised the investigators to
interrupt the trial and offer circumcision to the control group, who
were then asked to come to the investigation centre, where MC
(medical circumcision) was advised and proposed . Because the
study was interrupted, some participants did not have a full follow-
up on that date, and their visits that were not yet completed are
described as “planned” in this article.”202
“In January 2000, problems with vaccine supply necessitated
the temporary nationwide replacement of the whole cell compo-
nent of the combined DPT/Hib vaccine with acellular pertussis
vaccine. As this vaccine has a different local reactogenicity proﬁle,
we decided to stop the trial early.”203
ExplanationdArguably, trialists who arbitrarily conduct
unplanned interim analyses after very few events accrue using no
statistical guidelines run a high risk of “catching” the data at
a random extreme, which likely represents a large overestimate of
treatment beneﬁt.204omised trial.
not included or excluded Rationale
t meet the inclusion
inclusion criteria but
lled
These counts indicate whether trial participants
were likely to be representative of all
patients seen; they are relevant to assessment
of external validity only, and they are often
not available.
Crucial count for deﬁning trial size and
assessing whether a trial has been analysed
by intention to treat
id not receive treatment
dy group
Important counts for assessment of internal
validity and interpretation of results;
reasons for not receiving treatment as allocated
should be given.
id not complete treatment
dy group
Important counts for assessment of internal
validity and interpretation of results; reasons
for not completing treatment or follow-up
should be given.
id not complete follow-up
y group
ed from main
roup
Crucial count for assessing whether a trial
has been analysed by intention to treat;
reasons for excluding participants
should be given.
Box 5. Early stopping
RCTs can end when they reach their sample size goal, their
event count goal, their length of follow-up goal, or when
they reach their scheduled date of closure. In these situa-
tions the trial will stop in a manner independent of its
results, and stopping is unlikely to introduce bias in the
results. Alternatively, RCTs can stop earlier than planned
because of the result of an interim analysis showing larger
than expected benefit or harm on the experimental inter-
vention. Also RCTs can stop earlier than planned when
investigators find evidence of no important difference
between experimental and control interventions (that is,
stopping for futility). In addition, trials may stop early
because the trial becomes unviable: funding vanishes,
researchers cannot access eligible patients or study inter-
ventions, or the results of other studies make the research
question irrelevant.
Full reporting of why a trial ended is important for evidence
based decision making (see item 14b). Researchers exam-
ining why 143 trials stopped early for benefit found that
many failed to report key methodological information
regarding how the decision to stop was reacheddthe
planned sample size (n ¼ 28), interim analysis after which
the trial was stopped (n ¼ 45), or whether a stopping rule
informed the decision (n ¼ 48).134 Item 7b of the checklist
requires the reporting of timing of interim analyses, what
triggered them, how many took place, whether these were
planned or ad hoc, and whether there were statistical
guidelines and stopping rules in place a priori. Furthermore,
it is helpful to know whether an independent data moni-
toring committee participated in the analyses (and who
composed it, with particular attention to the role of the
funding source) and who made the decision to stop. Often
the data safety and monitoring committee makes recom-
mendations and the funders (sponsors) or the investigators
make the decision to stop.
Trials that stop early for reasons apparently independent of
trial findings, and trials that reach their planned termina-
tion, are unlikely to introduce bias by stopping.207 In these
cases, the authors should report whether interim analyses
took place and whether these results were available to the
funder.
The push for trials that change the intervention in response
to interim results, thus enabling a faster evaluation of
promising interventions for rapidly evolving and fatal
conditions, will require even more careful reporting of the
process and decision to stop trials early.208
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truncated in a data-driven manner versus one that reports its
ﬁndings after reaching a goal independent of results. Thus, RCTs
should indicate why the trial came to an end (see Box 5). The report
should also disclose factors extrinsic to the trial that affected the
decision to stop the trial, and who made the decision to stop the
trial, including reporting the role the funding agency played in the
deliberations and in the decision to stop the trial.134
A systematic review of 143 RCTs stopped earlier than planned
for beneﬁt found that these trials reported stopping after
accruing a median of 66 events, estimated a median relative risk
of 0.47 and a strong relation between the number of events
accrued and the size of the effect, with smaller trials with fewer
events yielding the largest treatment effects (odds ratio 31, 95%
conﬁdence interval 12e82).134 While an increasing number of
trials published in high impact medical journals report stopping
early, only 0.1% of trials reported stopping early for beneﬁt, which
contrasts with estimates arising from simulation studies205 and
surveys of data safety and monitoring committees.206 Thus, many
trials accruing few participants and reporting large treatment
effects may have been stopped earlier than planned but failed to
report this action.
5.4.4. Item 15. A table showing baseline demographic and clinical
characteristics for each group
ExampledSee Table 4
ExplanationdAlthough the eligibility criteria (see item 4a)
indicate who was eligible for the trial, it is also important to know
the characteristics of the participants who were actually included.
This information allows readers, especially clinicians, to judge how
relevant the results of a trial might be to an individual patient.
Randomised trials aim to compare groups of participants that
differ only with respect to the intervention (treatment). Although
proper random assignment prevents selection bias, it does not
guarantee that the groups are equivalent at baseline. Any differ-
ences in baseline characteristics are, however, the result of chance
rather than bias.32 The study groups should be compared at base-
line for important demographic and clinical characteristics so that
readers can assess how similar they were. Baseline data are espe-
cially valuable for outcomes that can also be measured at the start
of the trial (such as blood pressure).
Baseline information is most efﬁciently presented in a table (see
Table 4). For continuous variables, such as weight or blood pressure,
the variability of the data should be reported, along with average
values. Continuous variables can be summarised for each group by
the mean and standard deviation. When continuous data have an
asymmetrical distribution, a preferable approach may be to quote
the median and a centile range (such as the 25th and 75th centi-
les).177 Standard errors and conﬁdence intervals are not appropriate
for describing variabilitydthey are inferential rather than
descriptive statistics. Variables with a small number of ordered
categories (such as stages of disease I to IV) should not be treated as
continuous variables; instead, numbers and proportions should be
reported for each category.48,177
Unfortunately signiﬁcance tests of baseline differences are still
common23,32,210; they were reported in half of 50 RCTs trials pub-
lished in leading general journals in 1997.183 Such signiﬁcance tests
assess the probability that observed baseline differences could have
occurred by chance; however, we already know that any differ-
ences are caused by chance. Tests of baseline differences are not
necessarily wrong, just illogical.211 Such hypothesis testing is
superﬂuous and can mislead investigators and their readers.
Rather, comparisons at baseline should be based on consideration
of the prognostic strength of the variables measured and the size of
any chance imbalances that have occurred.2115.4.5. Item 16. For each group, number of participants
(denominator) included in each analysis and whether the analysis
was by original assigned groups
Examplesd“The primary analysis was intention-to-treat and
involved all patients who were randomly assigned.”212
“One patient in the alendronate group was lost to follow-up;
thus data from 31 patients were available for the intention-to-treat
analysis. Five patients were considered protocol violators .
consequently 26 patients remained for the per protocol
analyses.”213
ExplanationdThe number of participants in each group is an
essential element of the analyses. Although the ﬂow diagram (see
item 13a) may indicate the numbers of participants analysed, these
numbers often vary for different outcomemeasures. The number of
participants per group should be given for all analyses. For binary
Table 4
Example of reporting baseline demographic and clinical characteristics.a (Adapted
from Table 1 of Yusuf et al.209).
Telmisartan (N ¼ 2954) Placebo (N ¼ 2972)
Age (years) 66.9 (7.3) 66.9 (7.4)
Sex (female) 1280 (43.3%) 1267 (42.6%)
Smoking status:
Current 293 (9.9%) 289 (9.7%)
Past 1273 (43.1%) 1283 (43.2%)
Ethnic origin:
Asian 637 (21.6%) 624 (21.0%)
Arab 37 (1.3%) 40 (1.3%)
African 51 (1.7%) 55 (1.9%)
European 1801 (61.0%) 1820 (61.2%)
Native or Aboriginal 390 (13.2%) 393 (13.2%)
Other 38 (1.3%) 40 (1.3%)
Blood pressure (mm Hg) 140.7 (16.8/81.8) (10.1) 141.3 (16.4/82.0) (10.2)
Heart rate (beats per min) 68.8 (11.5) 68.8 (12.1)
Cholesterol (mmol/l):
Total 5.09 (1.18) 5.08 (1.15)
LDL 3.02 (1.01) 3.03 (1.02)
HDL 1.27 (0.37) 1.28 (0.41)
Coronary artery disease 2211 (74.8%) 2207 (74.3%)
Myocardial infarction 1381 (46.8%) 1360 (45.8%)
Angina pectoris 1412 (47.8%) 1412 (47.5%)
Peripheral artery disease 349 (11.8%) 323 (10.9%)
Hypertension 2259 (76.5%) 2269 (76.3%)
Diabetes 1059 (35.8%) 1059 (35.6%)
a Data are means (SD) or numbers (%).
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or event rates should also be reported. Expressing results as frac-
tions also aids the reader in assessing whether some of the
randomly assigned participants were excluded from the analysis. It
follows that results should not be presented solely as summary
measures, such as relative risks.
Participants may sometimes not receive the full intervention, or
some ineligible patientsmay have been randomly allocated in error.
One widely recommended way to handle such issues is to analyse
all participants according to their original group assignment,
regardless of what subsequently occurred (see Box 6). This
“intention-to-treat” strategy is not always straightforward to
implement. It is common for some patients not to complete
a studydthey may dropout or be withdrawn from active treat-
mentdand thus are not assessed at the end. If the outcome is
mortality, such patients may be included in the analysis based on
register information, whereas imputation techniques may need to
be used if other outcome data are missing. The term “intention-to-
treat analysis” is often inappropriately useddfor example, when
those who did not receive the ﬁrst dose of a trial drug are excluded
from the analyses.18
Conversely, analysis can be restricted to only participants who
fulﬁl the protocol in terms of eligibility, interventions, and outcome
assessment. This analysis is known as an “on-treatment” or “per
protocol” analysis. Excluding participants from the analysis can
lead to erroneous conclusions. For example, in a trial that compared
medical with surgical therapy for carotid stenosis, analysis limited
to participants who were available for follow-up showed that
surgery reduced the risk for transient ischaemic attack, stroke, and
death. However, intention-to-treat analysis based on all partici-
pants as originally assigned did not show a superior effect of
surgery.214
Intention-to-treat analysis is generally favoured because it
avoids bias associated with non-random loss of participants.215e217
Regardless of whether authors use the term “intention-to-treat,”
they should make clear which and how many participants are
included in each analysis (see item 13). Non-compliance with
assigned therapy may mean that the intention-to-treat analysis
underestimates the potential beneﬁt of the treatment, andadditional analyses, such as a per protocol analysis, may therefore
be considered.218,219 It should be noted, however, that such anal-
yses are often considerably ﬂawed.220
In a review of 403 RCTs published in 10 leading medical journals
in 2002, 249 (62%) reported the use of intention-to-treat analysis
for their primary analysis. This proportion was higher for journals
adhering to the CONSORT statement (70% v 48%). Among articles
that reported the use of intention-to-treat analysis, only 39%
actually analysed all participants as randomised, with more than
60% of articles having missing data in their primary analysis.221
Other studies show similar ﬁndings.18,222,223 Trials with no re-
ported exclusions are methodologically weaker in other respects
than those that report on some excluded participants,173 strongly
indicating that at least some researchers who have excluded
participants do not report it. Another study found that reporting an
intention-to-treat analysis was associated with other aspects of
good study design and reporting, such as describing a sample size
calculation.224
5.4.6. Item 17a. For each primary and secondary outcome, results
for each group, and the estimated effect size and its precision (such
as 95% conﬁdence interval)
ExamplesdSee Tables 5 and 6.
ExplanationdFor each outcome, study results should be re-
ported as a summary of the outcome in each group (for example,
the number of participants with or without the event and the
denominators, or the mean and standard deviation of measure-
ments), together with the contrast between the groups, known as
the effect size. For binary outcomes, the effect size could be the risk
ratio (relative risk), odds ratio, or risk difference; for survival time
data, it could be the hazard ratio or difference in median survival
time; and for continuous data, it is usually the difference in means.
Conﬁdence intervals should be presented for the contrast between
groups. A common error is the presentation of separate conﬁdence
intervals for the outcome in each group rather than for the treat-
ment effect.233 Trial results are often more clearly displayed in
a table rather than in the text, as shown in Tables 5 and 6.
For all outcomes, authors should provide a conﬁdence interval
to indicate the precision (uncertainty) of the estimate.48,235 A 95%
conﬁdence interval is conventional, but occasionally other levels
are used. Many journals require or strongly encourage the use of
conﬁdence intervals.236 They are especially valuable in relation to
differences that do not meet conventional statistical signiﬁcance,
for which they often indicate that the result does not rule out an
important clinical difference. The use of conﬁdence intervals has
increased markedly in recent years, although not in all medical
specialties.233 Although P values may be provided in addition to
conﬁdence intervals, results should not be reported solely as P
values.237,238 Results should be reported for all planned primary
and secondary endpoints, not just for analyses that were statisti-
cally signiﬁcant or “interesting.” Selective reporting within a study
is a widespread and serious problem.55,57 In trials in which interim
analyses were performed, interpretation should focus on the ﬁnal
results at the close of the trial, not the interim results.239
For both binary and survival time data, expressing the results
also as the number needed to treat for beneﬁt or harm can be
helpful (see item 21).240,241
5.4.7. Item 17b. For binary outcomes, presentation of both absolute
and relative effect sizes is recommended
Exampled“The risk of oxygen dependence or death was
reduced by 16% (95% CI 25%e7%). The absolute difference
was 6.3% (95% CI 9.9% to 2.7%); early administration to an
estimated 16 babies would therefore prevent 1 baby dying or being
long-term dependent on oxygen” (also see Table 7).242
Box 6. Intention-to-treat analysis
The special strength of the RCT is the avoidance of bias
when allocating interventions to trial participants (see Box
1). That strength allows strong inferences about cause
and effect that are not justified with other study designs. In
order to preserve fully the huge benefit of randomisation
we should include all randomised participants in the anal-
ysis, all retained in the group to which they were allocated.
Those two conditions define an “intention-to-treat” anal-
ysis, which is widely recommended as the preferred anal-
ysis strategy.18,223 Intention-to-treat analysis corresponds
to analysing the groups exactly as randomised. Strict
intention-to-treat analysis is often hard to achieve for two
main reasonsdmissing outcomes for some participants
and non-adherence to the trial protocol.
Missing outcomes
Many trialists exclude patients without an observed
outcome. Often this is reasonable, but once any rando-
mised participants are excluded the analysis is not strictly
an intention-to-treat analysis. Indeed, most randomised
trials have some missing observations. Trialists effectively
must choose between omitting the participants without
final outcome data or imputing their missing outcome
data.225 A “complete case” (or “available case”) analysis
includes only those whose outcome is known. While a few
missing outcomes will not cause a problem, in half of trials
more than 10% of randomised patients may have missing
outcomes.226 This common approach will lose power by
reducing the sample size, and biasmaywell be introduced if
being lost to follow-up is related to a patient’s response to
treatment. There should be concern when the frequency or
the causes of dropping out differ between the intervention
groups.
Participants with missing outcomes can be included in the
analysis only if their outcomes are imputed (that is, their
outcomes are estimated from other information that was
collected). Imputation of the missing data allows the anal-
ysis to conform to intention-to-treat analysis but requires
strong assumptions, which may be hard to justify.227
Simple imputation methods are appealing, but their use
may be inadvisable. In particular, a widely used method is
“last observation carried forward” in which missing final
values of the outcome variable are replaced by the last
known value before the participant was lost to follow-up.
This is appealing through its simplicity, but the method
may introduce bias,228 and no allowance is made for the
uncertainty of imputation.229 Many authors have severely
criticised last observation carried forward.229e231
Non-adherence to the protocol
A separate issue is that the trial protocol may not have been
followed fully for some trial participants. Common exam-
ples are participants who did not meet the inclusion criteria
(such as wrong diagnosis, too young), received
a proscribed co-intervention, did not take all the intended
treatment, or received a different treatment or no inter-
vention. The simple way to deal with any protocol devia-
tions is to ignore them: all participants can be included in
the analysis regardless of adherence to the protocol, and
this is the intention-to-treat approach. Thus, exclusion of
any participants for such reasons is incompatible with
intention-to-treat analysis.
The term “modified intention-to-treat” is quite widely used
to describe an analysis that excludes participants who did
not adequately adhere to the protocol, in particular those
who did not receive a defined minimum amount of the
intervention.232 An alternative term is “per protocol.”
Though a per protocol analysis may be appropriate in some
settings, it should be properly labelled as a non-
randomised, observational comparison. Any exclusion of
patients from the analysis compromises the randomisation
and may lead to bias in the results.
Like “intention-to-treat,” none of these other labels reliably
clarifies exactly which patients were included. Thus, in the
CONSORT checklist we have dropped the specific request
for intention-to-treat analysis in favour of a clear description
of exactly who was included in each analysis.
D. Moher et al. / International Journal of Surgery 10 (2012) 28e55 45
GUIDELINEExplanationdWhen the primary outcome is binary, both the
relative effect (risk ratio (relative risk) or odds ratio) and the
absolute effect (risk difference) should be reported (with conﬁ-
dence intervals), as neither the relative measure nor the absolute
measure alone gives a complete picture of the effect and its
implications. Different audiences may prefer either relative or
absolute risk, but both doctors and lay people tend to overestimate
the effect when it is presented in terms of relative risk.243e245 The
size of the risk difference is less generalisable to other populations
than the relative risk since it depends on the baseline risk in the
unexposed group, which tends to vary across populations. For
diseases where the outcome is common, a relative risk near unity
might indicate clinically important differences in public health
terms. In contrast, a large relative risk when the outcome is rare
may not be so important for public health (although it may be
important to an individual in a high risk category).
5.4.8. Item 18. Results of any other analyses performed, including
subgroup analyses and adjusted analyses, distinguishing pre-
speciﬁed from exploratory
Exampled“On the basis of a study that suggested perioperative
b-blocker efﬁcacy might vary across baseline risk, we pre-speciﬁed
our primary subgroup analysis on the basis of the revised cardiac
risk index scoring system. We also did pre-speciﬁed secondary
subgroup analyses based on sex, type of surgery, and use of an
epidural or spinal anaesthetic. For all subgroup analyses, we used
Cox proportional hazard models that incorporated tests for inter-
actions, designated to be signiﬁcant at p < 0.05. Fig. 3 shows the
results of our pre-speciﬁed subgroup analyses and indicates
consistency of effects . Our subgroup analyses were underpow-
ered to detect the modest differences in subgroup effects that one
might expect to detect if there was a true subgroup effect.”100
ExplanationdMultiple analyses of the same data create a risk
for false positive ﬁndings.246 Authors should resist the temptation
to perform many subgroup analyses.183,185,247 Analyses that were
pre-speciﬁed in the trial protocol (see item 24) are much more
reliable than those suggested by the data, and therefore authors
should report which analyses were pre-speciﬁed. If subgroup
analyses were undertaken, authors should report which subgroups
were examined, why, if they were pre-speciﬁed, and how many
were pre-speciﬁed. Selective reporting of subgroup analyses could
lead to bias.248 When evaluating a subgroup the question is not
whether the subgroup shows a statistically signiﬁcant result but
whether the subgroup treatment effects are signiﬁcantly different
from each other. To determine this, a test of interaction is helpful,
although the power for such tests is typically low. If formal evalu-
ations of interaction are undertaken (see item 12b) they should be
reported as the estimated difference in the intervention effect in
each subgroup (with a conﬁdence interval), not just as P values.
Table 5
Example of reporting of summary results for each study group (binary outcomes).a
(Adapted from Table 2 of Mease et al.103).
Endpoint Number (%) Risk difference
(95% CI)
Etanercept
(n ¼ 30)
Placebo
(n ¼ 30)
Primary endpoint
Achieved PsARC at 12 weeks 26 (87) 7 (23) 63% (44e83)
Secondary endpoint
Proportion of patients
meeting ACR criteria:
ACR20 22 (73) 4 (13) 60% (40e80)
ACR50 15 (50) 1 (3) 47% (28e66)
ACR70 4 (13) 0 (0) 13% (1e26)
PsARC ¼ psoriatic arthritis response criteria. ACR ¼ American College of
Rheumatology.
a See also example for item 6a.
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of which only 42% used tests of interaction.183 It was often difﬁcult
to determine whether subgroup analyses had been speciﬁed in the
protocol. In another survey of surgical trials published in high
impact journals, 27 of 72 trials reported 54 subgroup analyses, of
which 91% were post hoc and only 6% of subgroup analyses used
a test of interaction to assess whether a subgroup effect existed.249
Similar recommendations apply to analyses in which adjust-
ment was made for baseline variables. If done, both unadjusted and
adjusted analyses should be reported. Authors should indicate
whether adjusted analyses, including the choice of variables to
adjust for, were planned. Ideally, the trial protocol should state
whether adjustment is made for nominated baseline variables by
using analysis of covariance.187 Adjustment for variables because
they differ signiﬁcantly at baseline is likely to bias the estimated
treatment effect.187 A survey found that unacknowledged discrep-
ancies between protocols and publications were found for all 25
trials reporting subgroup analyses and for 23 of 28 trials reporting
adjusted analyses.92
5.4.9. Item 19. All important harms or unintended effects in each
group
For speciﬁc guidance see CONSORT for harms.42
Exampled“The proportion of patients experiencing any
adverse event was similar between the rBPI21 [recombinant
bactericidal/permeability-increasing protein] and placebo groups:
168 (88.4%) of 190 and 180 (88.7%) of 203, respectively, and it was
lower in patients treated with rBPI21 than in those treated with
placebo for 11 of 12 body systems . the proportion of patients
experiencing a severe adverse event, as judged by the investigators,
was numerically lower in the rBPI21 group than the placebo group:
53 (27.9%) of 190 versus 74 (36.5%) of 203 patients, respectively.
There were only three serious adverse events reported as drug-
related and they all occurred in the placebo group.”250
ExplanationdReaders need information about the harms as
well as the beneﬁts of interventions to make rational and balanced
decisions. The existence and nature of adverse effects can have
a major impact on whether a particular intervention will be
deemed acceptable and useful. Not all reported adverse eventsTable 6
Example of reporting of summary results for each study group (continuous outcomes). (
Exercise therapy (n ¼ 65)
Baseline (mean (SD)) 12 months (mean (SD))
Function score (0e100) 64.4 (13.9) 83.2 (14.8)
Pain at rest (0e100) 4.14 (2.3) 1.43 (2.2)
Pain on activity (0e100) 6.32 (2.2) 2.57 (2.9)
a Function score adjusted for baseline, age, and duration of symptoms.observed during a trial are necessarily a consequence of the inter-
vention; some may be a consequence of the condition being
treated. Randomised trials offer the best approach for providing
safety data as well as efﬁcacy data, although they cannot detect rare
harms.
Many reports of RCTs provide inadequate information on
adverse events. A survey of 192 drug trials published from 1967 to
1999 showed that only 39% had adequate reporting of clinical
adverse events and 29% had adequate reporting of laboratory
deﬁned toxicity.72 More recently, a comparison between the
adverse event data submitted to the trials database of the National
Cancer Institute, which sponsored the trials, and the information
reported in journal articles found that low grade adverse events
were underreported in journal articles. High grade events
(Common Toxicity Criteria grades 3e5) were reported inconsis-
tently in the articles, and the information regarding attribution to
investigational drugs was incomplete.251 Moreover, a review of
trials published in six general medical journals in 2006e2007
found that, although 89% of 133 reports mentioned adverse events,
no information on severe adverse events and withdrawal of
patients due to an adverse event was given on 27% and 48% of
articles, respectively.252
An extension of the CONSORT statement has been developed to
provide detailed recommendations on the reporting of harms in
randomised trials.42 Recommendations and examples of appro-
priate reporting are freely available from the CONSORT website
(www.consort-statement.org). They complement the CONSORT
2010 Statement and should be consulted, particularly if the study of
harms was a key objective. Brieﬂy, if data on adverse events were
collected, events should be listed and deﬁned, with reference to
standardised criteria where appropriate. Themethods used for data
collection and attribution of events should be described. For each
study arm the absolute risk of each adverse event, using appro-
priate metrics for recurrent events, and the number of participants
withdrawn due to harms should be presented. Finally, authors
should provide a balanced discussion of beneﬁts and harms.425.5. Discussion
5.5.1. Item 20. Trial limitations, addressing sources of potential bias,
imprecision, and, if relevant, multiplicity of analyses
Exampled“The preponderance of male patients (85%) is
a limitation of our study.We used bare-metal stents, since drug-
eluting stents were not available until late during accrual. Although
the latter factor may be perceived as a limitation, published data
indicate no beneﬁt (either short-term or long-term) with respect to
death and myocardial infarction in patients with stable coronary
artery disease who receive drug-eluting stents, as compared with
those who receive bare-metal stents.”253
ExplanationdThe discussion sections of scientiﬁc reports are
often ﬁlled with rhetoric supporting the authors’ ﬁndings254 and
provide little measured argument of the pros and cons of the study
and its results. Some journals have attempted to remedy this
problem by encouraging more structure to authors’ discussion of
their results.255,256 For example, Annals of Internal MedicineAdapted from Table 3 of van Linschoten234).
Control (n ¼ 66) Adjusted differencea
(95% CI) at 12 months
Baseline (mean (SD)) 12 months (mean (SD))
65.9 (15.2) 79.8 (17.5) 4.52 (0.73e9.76)
4.03 (2.3) 2.61 (2.9) 1.29 (2.16 to 0.42)
5.97 (2.3) 3.54 (3.38) 1.19 (2.22 to 0.16)
Table 7
Example of reporting both absolute and relative effect sizes. (Adapted from Table 3 of The OSIRIS Collaborative Group242).
Primary outcome Percentage (No) Risk ratio (95% CI) Risk difference (95% CI)
Early administration
(n ¼ 1344)
Delayed selective
administration (n ¼ 1346)
Death or oxygen dependence at
“expected date of delivery”
31.9 (429) 38.2 (514) 0.84 (0.75e0.93) 6.3 (9.9 to 2.7)
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senting (1) a brief synopsis of the key ﬁndings, (2) consideration of
possible mechanisms and explanations, (3) comparison with rele-
vant ﬁndings from other published studies (whenever possible
including a systematic review combining the results of the current
study with the results of all previous relevant studies), (4) limita-
tions of the present study (and methods used to minimise and
compensate for those limitations), and (5) a brief section that
summarises the clinical and research implications of the work, as
appropriate.255 We recommend that authors follow these sensible
suggestions, perhaps also using suitable subheadings in the
discussion section.
Although discussion of limitations is frequently omitted from
research reports,257 identiﬁcation and discussion of theweaknesses
of a study have particular importance.258 For example, a surgical
group reported that laparoscopic cholecystectomy, a technically
difﬁcult procedure, had signiﬁcantly lower rates of complications
than the more traditional open cholecystectomy for management
of acute cholecystitis.259 However, the authors failed to discuss an
obvious bias in their results. The study investigators had completed
all the laparoscopic cholecystectomies, whereas 80% of the open
cholecystectomies had been completed by trainees.
Authors should also discuss any imprecision of the results.
Imprecision may arise in connectionwith several aspects of a study,
including measurement of a primary outcome (see item 6a) or
diagnosis (see item 4a). Perhaps the scale used was validated on an
adult population but used in a paediatric one, or the assessor was
not trained in how to administer the instrument.
The difference between statistical signiﬁcance and clinical
importance should always be borne in mind. Authors should
particularly avoid the common error of interpreting a non-
signiﬁcant result as indicating equivalence of interventions. The
conﬁdence interval (see item 17a) provides valuable insight into
whether the trial result is compatible with a clinically important
effect, regardless of the P value.120
Authors should exercise special carewhen evaluating the results
of trials with multiple comparisons. Such multiplicity arises from
several interventions, outcome measures, time points, subgroup
analyses, and other factors. In such circumstances, some statisti-
cally signiﬁcant ﬁndings are likely to result from chance alone.
5.5.2. Item 21. Generalisability (external validity, applicability) of
the trial ﬁndings
Examplesd“As the intervention was implemented for both
sexes, all ages, all types of sports, and at different levels of sports,
the results indicate that the entire range of athletes, from young
elite to intermediate and recreational senior athletes, would beneﬁt
from using the presented training programme for the prevention of
recurrences of ankle sprain. By including non-medically treated
and medically treated athletes, we covered a broad spectrum of
injury severity. This suggests that the present training programme
can be implemented in the treatment of all athletes. Furthermore,
as it is reasonable to assume that ankle sprains not related to sports
are comparable with those in sports, the programme could beneﬁt
the general population.”260“This replicates and extends the work of Clarke and colleagues
and demonstrates that this CB (cognitive behavioural) prevention
program can be reliably and effectively delivered in different
settings by clinicians outside of the groupwho originally developed
the intervention. The effect size was consistent with those of
previously reported, single-site, indicated depression prevention
studies and was robust across sites with respect to both depressive
disorders and symptoms . In this generalisability trial, we chose
a comparison condition that is relevant to public healthdusual care
. The sample also was predominantly working class to middle
class with access to health insurance. Given evidence that CB
therapy can be more efﬁcacious for adolescents from homes with
higher incomes, it will be important to test the effects of this
prevention programwithmore economically and ethnically diverse
samples.”261
ExplanationdExternal validity, also called generalisability or
applicability, is the extent to which the results of a study can be
generalised to other circumstances.262 Internal validity, the extent
to which the design and conduct of the trial eliminate the possi-
bility of bias, is a prerequisite for external validity: the results of
a ﬂawed trial are invalid and the question of its external validity
becomes irrelevant. There is no absolute external validity; the term
is meaningful only with regard to clearly speciﬁed conditions that
were not directly examined in the trial. Can results be generalised
to an individual participant or groups that differ from those
enrolled in the trial with regard to age, sex, severity of disease, and
comorbid conditions? Are the results applicable to other drugs
within a class of similar drugs, to a different dose, timing, and route
of administration, and to different concomitant therapies? Can
similar results be expected at the primary, secondary, and tertiary
levels of care?What about the effect on related outcomes that were
not assessed in the trial, and the importance of length of follow-up
and duration of treatment, especially with respect to harms?263
External validity is a matter of judgement and depends on the
characteristics of the participants included in the trial, the trial
setting, the treatment regimens tested, and the outcomes
assessed.5,136 It is therefore crucial that adequate information be
described about eligibility criteria and the setting and location (see
item 4b), the interventions and how they were administered (see
item 5), the deﬁnition of outcomes (see item 6), and the period of
recruitment and follow-up (see item 14). The proportion of control
group participants in whom the outcome develops (control group
risk) is also important. The proportion of eligible participants who
refuse to enter the trial as indicated on the ﬂowchart (see item 13)
is relevant for the generalisability of the trial, as it may indicate
preferences for or acceptability of an intervention. Similar consid-
erations may apply to clinician preferences.264,265
Several issues are important when results of a trial are applied to
an individual patient.266e268 Although some variation in treatment
response between an individual patient and the patients in a trial or
systematic review is to be expected, the differences tend to be in
magnitude rather than direction.
Although there are important exceptions,268 therapies (espe-
cially drugs269) found to be beneﬁcial in a narrow range of patients
generally have broader application in actual practice. Frameworks
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including qualitative studies, such as in integral “process evalua-
tions”270 and checklists.271 Measures that incorporate baseline risk
when calculating therapeutic effects, such as the number needed to
treat to obtain one additional favourable outcome and the number
needed to treat to produce one adverse effect, are helpful in
assessing the beneﬁt-to-risk balance in an individual patient or
group with characteristics that differ from the typical trial partici-
pant.268,272,273 Finally, after deriving patient centred estimates for
the potential beneﬁt and harm from an intervention, the clinician
must integrate them with the patient’s values and preferences for
therapy. Similar considerations apply when assessing the general-
isability of results to different settings and interventions.
5.5.3. Item 22. Interpretation consistent with results, balancing
beneﬁts and harms, and considering other relevant evidence
Exampled“Studies published before 1990 suggested that
prophylactic immunotherapy also reduced nosocomial infections in
very-low-birth-weight infants. However, these studies enrolled
small numbers of patients; employed varied designs, preparations,
and doses; and included diverse study populations. In this large
multicenter, randomised controlled trial, the repeated prophylactic
administration of intravenous immune globulin failed to reduce the
incidence of nosocomial infections signiﬁcantly in premature
infants weighing 501e1500 g at birth.”274
ExplanationdReaders will want to know how the present
trial’s results relate to those of other RCTs. This can best be achieved
by including a formal systematic review in the results or discussion
section of the report.83,275e277 Such synthesis may be impractical
for trial authors, but it is often possible to quote a systematic review
of similar trials. A systematic review may help readers assess
whether the results of the RCT are similar to those of other trials in
the same topic area and whether participants are similar across
studies. Reports of RCTs have often not dealt adequately with these
points.277 Bayesian methods can be used to statistically combine
the trial data with previous evidence.278
We recommend that, at a minimum, the discussion should be as
systematic as possible and be based on a comprehensive search,
rather than being limited to studies that support the results of the
current trial.279
5.6. Other information
5.6.1. Item 23. Registration number and name of trial registry
Exampled“The trial is registered at ClinicalTrials.gov, number
NCT00244842. ”280
ExplanationdThe consequences of non-publication of entire
trials,281,282 selective reporting of outcomes within trials, and of per
protocol rather than intention-to-treat analysis have been well
documented.55,56,283 Covert redundant publication of clinical trials
can also cause problems, particularly for authors of systematic
reviews when results from the same trial are inadvertently
included more than once.284
To minimise or avoid these problems there have been repeated
calls over the past 25 years to register clinical trials at their
inception, to assign unique trial identiﬁcation numbers, and to
record other basic information about the trial so that essential
details are made publicly available.285e288 Provoked by recent
serious problems of withholding data,289 there has been a renewed
effort to register randomised trials. Indeed, the World Health
Organisation states that “the registration of all interventional trials
is a scientiﬁc, ethical and moral responsibility” (www.who.int/
ictrp/en). By registering a randomised trial, authors typically
report a minimal set of information and obtain a unique trial
registration number.In September 2004 the International Committee of Medical
Journal Editors (ICMJE) changed their policy, saying that theywould
consider trials for publication only if they had been registered
before the enrolment of the ﬁrst participant.290 This resulted in
a dramatic increase in the number of trials being registered.291 The
ICMJE gives guidance on acceptable registries (www.icmje.org/faq.
pdf).
In a recent survey of 165 high impact factor medical journals’
instructions to authors, 44 journals speciﬁcally stated that all
recent clinical trials must be registered as a requirement of
submission to that journal.292
Authors should provide the name of the register and the trial’s
unique registration number. If authors had not registered their trial
they should explicitly state this and give the reason.
5.6.2. Item 24. Where the full trial protocol can be accessed, if
available
Exampled“Full details of the trial protocol can be found in the
Supplementary Appendix, available with the full text of this article
at www.nejm.org.”293
ExplanationdA protocol for the complete trial (rather than
a protocol of a speciﬁc procedure within a trial) is important
because it pre-speciﬁes the methods of the randomised trial, such
as the primary outcome (see item 6a). Having a protocol can help to
restrict the likelihood of undeclared post hoc changes to the trial
methods and selective outcome reporting (see item 6b). Elements
that may be important for inclusion in the protocol for a rando-
mised trial are described elsewhere.294
There are several options for authors to consider ensuring their
trial protocol is accessible to interested readers. As described in the
example above, journals reporting a trial’s primary results can
make the trial protocol available on their website. Accessibility to
the trial results and protocol is enhanced when the journal is open
access. Some journals (such as Trials) publish trial protocols, and
such a publication can be referenced when reporting the trial’s
principal results. Trial registration (see item 23) will also ensure
that many trial protocol details are available, as the minimum trial
characteristics included in an approved trial registration database
includes several protocol items and results (www.who.int/ictrp/
en). Trial investigators may also be able to post their trial
protocol on a website through their employer. Whatever mecha-
nism is used, we encourage all trial investigators to make their
protocol easily accessible to interested readers.
5.6.3. Item 25. Sources of funding and other support (such as supply
of drugs), role of funders
Examplesd“Grant support was received for the intervention
from Plan International and for the research from the Wellcome
Trust and Joint United Nations Programme on HIV/AIDS (UNAIDS).
The funders had no role in study design, data collection and anal-
ysis, decision to publish, or preparation of the manuscript.”295
“This study was funded by GlaxoSmithKline Pharmaceuticals.
GlaxoSmithKline was involved in the design and conduct of the
study and provided logistical support during the trial. Employees of
the sponsor worked with the investigators to prepare the statistical
analysis plan, but the analyses were performed by the University of
Utah. The manuscript was prepared by Dr Shaddy and the steering
committeemembers. GlaxoSmithKlinewas permitted to review the
manuscript and suggest changes, but the ﬁnal decision on content
was exclusively retained by the authors.”296
ExplanationdAuthors should report the sources of funding for
the trial, as this is important information for readers assessing a trial.
Studieshave showed that research sponsoredby thepharmaceutical
industry are more likely to produce results favouring the product
made by the company sponsoring the research than studies funded
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funding found that research funded by the pharmaceutical industry
had four times the odds of having outcomes favouring the sponsor
than research funded by other sources (odds ratio 4.05, 95% conﬁ-
dence interval 2.98e5.51).297 A large proportion of trial publications
do not currently report sources of funding. The degree of under-
reporting is difﬁcult to quantify. A survey of 370 drug trials found
that 29% failed to report sources of funding.301 In another survey, of
PubMed indexed randomised trials published in December 2000,
source of funding was reported for 66% of the 519 trials.16
The level of involvement by a funder and their inﬂuence on the
design, conduct, analysis, and reporting of a trial varies. It is
therefore important that authors describe in detail the role of the
funders. If the funder had no such involvement, the authors should
state so. Similarly, authors should report any other sources of
support, such as supply and preparation of drugs or equipment, or
in the analysis of data and writing of the manuscript.302
6. Reporting RCTs that did not have a two group parallel
design
The primary focus of the CONSORT recommendations is RCTs
with a parallel design and two treatment groups. Most RCTs have
that design, but a substantial minority do not: 45% (233/519) of
RCTs published in December 2000,16 and 39% (242/616) in
December 2006.17
Most of the CONSORT statement applies equally to all trial
designs, but there are a few additional issues to address for each
design. Before the publication of the revised CONSORT statement in
2001, the CONSORT Group decided to develop extensions to the
main CONSORT statement relevant to speciﬁc trial designs. Exten-
sions have been published relating to reporting of cluster rando-
mised trials40 and non-inferiority and equivalence trials.39 Lack of
resources has meant that other planned extensions have not been
completed; they will cover trials with the following designs: multi-
arm parallel, factorial, crossover, within-person.
Authors reporting trials with a cluster design or using a non-
inferiority or equivalence framework should consult the
CONSORT recommendations in addition to those in this document.
Here we make a few interim comments about the other designs. In
each case, the trial design should be made clear in both the main
text and the article’s abstract.
Multiarm (>2 group) parallel group trials need the least modi-
ﬁcation of the standard CONSORT guidance. The ﬂow diagram can
be extended easily. The main differences from trials with two
groups relate to clariﬁcation of how the study hypotheses relate to
the multiple groups, and the consequent methods of data analysis
and interpretation. For factorial trials, the possibility of interaction
between the interventions generally needs to be considered. In
addition to overall comparisons of participants who did or did not
receive each intervention under study, investigators should
consider also reporting results for each treatment combination.303
In crossover trials, each participant receives two (or more)
treatments in a random order. The main additional issues to
address relate to the paired nature of the data, which affect design
and analysis.304 Similar issues affect within-person comparisons, in
which participants receive two treatments simultaneously (often to
paired organs). Also, because of the risk of temporal or systemic
carryover effects, respectively, in both cases the choice of design
needs justiﬁcation.
The CONSORT Group intends to publish extensions to CONSORT
to cover all these designs. In addition, we will publish updates to
existing guidance for cluster randomised trials and non-inferiority
and equivalence trials to take account of this major update of the
generic CONSORT guidance.7. Discussion
Assessment of healthcare interventions can be misleading
unless investigators ensure unbiased comparisons. Random allo-
cation to study groups remains the only method that eliminates
selection and confounding biases. Non-randomised trials tend to
result in larger estimated treatment effects than randomised
trials.305,306
Bias jeopardises even RCTs, however, if investigators carry out
such trials improperly.307 A recent systematic review, aggregating
the results of several methodological investigations, found that, for
subjective outcomes, trials that used inadequate or unclear allo-
cation concealment yielded 31% larger estimates of effect than
those that used adequate concealment, and trials that were not
blinded yielded 25% larger estimates.153 As might be expected,
there was a strong association between the two.
The design and implementation of an RCT require methodolog-
ical as well as clinical expertise, meticulous effort,143,308 and a high
level of alertness for unanticipated difﬁculties. Reports of RCTs
should be written with similarly close attention to reducing bias.
Readers should not have to speculate; the methods used should be
complete and transparent so that readers can readily differentiate
trials with unbiased results from those with questionable results.
Sound science encompasses adequate reporting, and the conduct of
ethical trials rests on the footing of sound science.309
We hope this update of the CONSORT explanatory article will
assist authors in using the 2010 version of CONSORT and explain in
general terms the importance of adequately reporting of trials. The
CONSORT statement can help researchers designing trials in
future310 and can guide peer reviewers and editors in their evalu-
ation of manuscripts. Indeed, we encourage peer reviewers and
editors to use the CONSORT checklist to assess whether authors
have reported on these items. Such assessments will likely improve
the clarity and transparency of published trials. Because CONSORT
is an evolving document, it requires a dynamic process of continual
assessment, reﬁnement, and, if necessary, change, which is why we
have this update of the checklist and explanatory article. As new
evidence and critical comments accumulate, we will evaluate the
need for future updates.
The ﬁrst version of the CONSORT statement, from 1996, seems to
have led to improvement in the quality of reporting of RCTs in the
journals that have adopted it.50e54 Other groups are using the
CONSORT template to improve the reporting of other research
designs, such as diagnostic tests311 and observational studies.312
The CONSORT website (www.consort-statement.org) has been
established to provide educational material and a repository
database of materials relevant to the reporting of RCTs. The site
includes many examples from real trials, including all of the
examples included in this article. We will continue to add good and
bad examples of reporting to the database, and we invite readers to
submit further suggestions by contacting us through the website.
The CONSORT Group will continue to survey the literature to ﬁnd
relevant articles that address issues relevant to the reporting of
RCTs, and we invite authors of any such articles to notify us about
them. All of this information will be made accessible through the
CONSORT website, which is updated regularly.
More than 400 leading general and specialty journals and
biomedical editorial groups, including the ICMJE,World Association
of Medical Journal Editors, and the Council of Science Editors, have
given their ofﬁcial support to CONSORT. We invite other journals
concerned about the quality of reporting of clinical trials to endorse
the CONSORT statement and contact us through our website to let
us know of their support. The ultimate benefactors of these
collective efforts should be people who, for whatever reason,
require intervention from the healthcare community.
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